{
  "name" : "moscow.sci-hub.se_5151_05530e288153ddb57e4bf7d8bbd48087_subramanian2016.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Recent trends in nano based drug delivery systems for efficient delivery of phytochemicals in chemotherapy",
    "authors" : [ "A.P Subramanian", "S. K. Jaganathan" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "www.rsc.org/advances\nRSC Advances\nThis is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.\nYou can find more information about Accepted Manuscripts in the Information for Authors.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: A. P. S, S. K.\nJaganathan, M. A, K. Pandiyaraj, G. Nageswaran and E. Supriyanto, RSC Adv., 2016, DOI:\n10.1039/C6RA07802H.\nRSC Advances RSC Publishing\nREVIEW ARTICLE\nThis journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015, 00, 1-11 | 1\nCite this: DOI: 10.1039/x0xx00000x\nReceived 00th January 2015, Accepted 00th January 2015\nDOI: 10.1039/x0xx00000x\nwww.rsc.org/\nRecent trends in nano based drug delivery systems for\nefficient delivery of phytochemicals in chemotherapy\nA.P Subramanian a , S. K. Jaganathan* ,a , A. Manikandan b , N. Pandiaraj c , Gomathi N d , E. Supriyanto a\nThe advent of nanotechnology has revolutionized various scientific inventions, out of which\nthe debut of nanomedicine is outstanding. Especially, the researches related to nano-drug\ndelivery for treating cancer has been embarking. The natural compounds present in the\nplants, namely phytochemicals has been extensively exploited for its anticancer property.\nDespite their excellent anticancer ability, the phytochemicals are limited by their low water\nsolubility and poor bioavailability. However, the field of nanotechnology has reformed these\nlimitations. This review focusses on various nano-drug delivery of phytochemicals against the\nkiller disease cancer. The common carriers that were employed ranged from micelles with\npolymeric base, dendrimers, liposomes and nanoparticles. The phytochemicals were found to\nbecome more soluble when delivered by the nanocarriers and exhibited a remarkable effect\non the cancer cells compared to its free form. More interestingly, the half maximal dose of\nthe phytochemical reduced significantly when delivered by the nanocarrier. On the whole,\nthis review encourages the idea of “cancer-nanotechnology” after an in depth clinical studies\non these phytochemical loaded nanocarriers. Moreover, it will epitomize the nanocarriers as\na crusader in improving the cancer chemotherapy by reducing the undesired effects and\ninvigorate the site-specific drug delivery."
    }, {
      "heading" : "1. Introduction",
      "text" : "Nature has a stake of comrades to help the technically evolving world that is inclined to several newly arising diseases. Consumption of naturally available plant derived products have been used to prevent as well as treat various diseases for many centauries by the man kind [1]. The curative property of these plant products are believed to be linked to the natural compounds present in them. These compounds are known as phytochemicals, or plant-derived chemicals. These are chemical compounds produced by the plants that give colour or other organoleptic properties to it [2]. Nevertheless, the contemporary researchers have shown that these natural compounds can protect against many diseases.\nSeveral population studies conducted shows, there are few phytochemicals from fruits, vegetables and whole grains that are active against cardiovascular disease, diabetes and neurodegeneration. Apart from this, there are many literature proofs to show the various health benefits of phytochemicals present in them [3, 4,5]. Among these, the potential ability of the natural compounds against killer disease cancer is significant. Regardless of these biological benefits possessed by the bioactive plant components, their usage in the medicinal field has a long way to go [6]. Some of the factors that influence this are the low water\nsolubility, poor bioavailability and requirement of high doses. Further, many investigations has showed that these issues can be easily surpassed by the nano-based delivery of the phytochemicals. The nano-based formulations are found to improve solubility, bioavailability, specific targeting while reducing the doses and achieving steady-state therapeutic levels in cancer treatment [7].\nIn general, all the biological process that happens inside the body, including the origin and prognosis of cancer, are said to occur in the nano-level [8]. It is due to this reason the application of nanotechnology in the field of medicine has flourished its branches deeply. Nanotechnology is one of the advanced multidisciplinary technology that typically involves nano-level (10−9 m) invesFgaFon [9]. Cancer is a major threat to mankind and claims to be the second leading cause of death worldwide. According to the survey, about 595,690 Americans are expected to die of cancer and 1,685,210 new cancer cases diagnosed in US during the year 2016 [10]. The available treatment procedures of cancer varies from chemotherapy to targeted radiotherapy. Regardless of these different treatment procedure there is no single medical procedure to treat cancer. Hence, the continuing threat of cancer deaths motivate scientists to steadily concentrate on the field of oncology. One such more advanced mode of treatment type is the cancernanotechnology, which combines nanomedicine and cancer [11].\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n2 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nThe application of nanotechnology in the oncology field offers different approaches to make significant advances in both cancer diagnosis and treatment. These renewed approaches mainly deal with the nanoparticles that are designed to specifically target and treat cancer by increasing the solubility and bioavailability of encapsulated drugs [12]. Though there are large number of studies to show the anticancer property of phytochemicals, this review mainly deals with the nanotechnology based drug delivery of several naturally available chemical compounds in various types of cancer. Before leading in to it, a brief advent of chemotherapy is provided to ease the readers."
    }, {
      "heading" : "2. Chemotherapy",
      "text" : "Chemotherapy is a common choice of treatment adopted by cancer patients around the globe. It mainly utilizes one or more chemical substance known as anticancer drug or chemotherapeutic drug [13]. These chemical substances are found to have anti-cancer property along with the ability to destroy the cells that divide rapidly, one of the major property of cancer cells. This treatment is adopted before, after or during other types of treatment procedures such as radiotherapy, surgery and targeted radiotherapy [14]. The effectiveness of chemotherapy entirely dependent on the type as well as the stage of cancer. The efficacy is fair and curative for cancers like leukemia while the treatment is unsuccessful in case of brain tumor or non- on-melanoma skin cancers. Nevertheless, the effectiveness of the treatment can be measured only after 2 or 3 cycles of chemotherapy [15].\nFigure 1: Outline of chemotherapy\nSome of the commercially available chemotherapeutic drugs include 5-fluorouracil, doxorubicin, paclitaxel, oxaliplatin, cisplatin, epirubicin, etc. All these chemotherapeutic drugs affect the cancer cells and induce apoptosis [16]. Apoptosis is a programmed cell death in multicellular organisms involving a series of biochemical changes as well as morphological change finally leading to the death of the cell [17]. A schematic representation on the action of anti-cancer drugs on cancer cells is given in figure 1. The chemotherapeutic drugs are most generally consumed orally. However all drugs cannot be orally administered and hence some are injected subcutaneously, intra-muscular or intravenously. Another major complexity of chemotherapy is the dosage at which the chemotherapeutic drugs can be administered. The dose is prescribed depending upon the weight and height of a person and also based on the type of drug [18]. This is mainly because, if the dosage is low then the treatment becomes ineffective, where as if the dosage is high the chemotherapeutic drugs cause side effects.\nAdverse effect or side effect of chemotherapy is a foremost concern by the physicians and cancer patients around the globe. The exhibit a wide range of side-effects depending on the type of medications used. As the chemotherapeutic drugs affect the fast growing cells in common, the other growing cells like hair cells, blood cells, bone marrow cells and the cells lining the mouth, stomach, and intestines are also affected. It is due to this reason the pregnant women are recommended to undergo abortion before chemotherapy [19]. Besides this, they also lead to immunosuppression, infertility, myelosuppression, gastrointestinal distress, typhlitis, anaemia, fatigue, peripheral neuropathy, nausea and vomiting [20]. All these undesirable factors of the chemotherapeutic drug triggers the researches to search for a harmless substance with significant anticancer property for cancer treatment. In addition to the new anticancer drugs, there also many researches on the administration method that can individually targets the cancer cells."
    }, {
      "heading" : "3. Phytochemicals",
      "text" : "The word phyto means “plants” in Greek and phytochemicals are the naturally occurring plant-derived compounds. They are the secondary metabolites or the bioactive compounds of plants. These compounds are produced by plants as a protection against the different environmental stresses which includes insects, bacteria, funguses and weather changes [21]. Nevertheless, the occurrence of phytochemicals cannot be confined, as it is spread throughout the range of flora and fauna found in the nature. A plant contains a variety of phytochemicals and a same phytochemical is present in more than one plant [22]. The chemical formula and the sources of the various phytochemicals enlisted in this review are tabulated in table 1. In case of eugenol, the main source is clove while it is also found in wormwood, cinnamon, vanilla, celery, basil etc. [23]. Whereas clove contains acetyl eugenol, beta-caryophyllene, vanillin, crategolic acid, bicornin, gallotannic acid, methyl salicylate, eugenin, kaempferol, rhamnetin, eugenitin, oleanolic acid, stigmasterol, campesterol, and several sesquiterpenes [24]. In order to maintain a class these plant derived compounds have been classified into groups and subgroups based on their functional groups, structures and biosynthetic origins [25]. The summary of the phytochemical classification is given in the figure 2.\nFigure 2: Classification of phytochemicals\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 3\nThe phytochemicals are more abundant in the fruits and vegetables extracts, chocolate, tea, etc. that are consumed in day to day life. These compounds are usually described as non-essential nutrients as they minimally contribute to the growth or development or wellbeing of the individual. They have been long remained unnoticed by the healthy eaters or the dietitians due to the fact that they are not required to sustain life. However, there have been copious number of researches working on these plant derived bioactive compounds and their biological benefits. The phytochemicals when consumed along with the diet have been proven effective in fighting many chronic diseases especially, the cardiovascular disorders and cancer [26]. The phytochemicals are found to be a great source of antioxidants. Most of the phytochemicals are found to excellently inhibit the proliferation of cells as well as angiogenesis, the two main trademark characteristics of cancer [27]. The investigation of anti-carcinogenic effects of phytochemicals in laboratory condition and in various animal models have been conducted. The results obtained showed an improvement in excretion of carcinogens, inhibition of mitosis, subdual of inflammatory processes such as cyclooxygenase-2 expression and induction of apoptosis at different stages of cancer [28]. The phytochemicals are proved to fight against various types of cancers such as lung, prostate cancer, oral cancer, melanoma, leukemia, lymphoma, colon cancer and breast cancer [29]. Before going for the various study related to the anticancer property of phytochemicals, understating their bioavailability is more important."
    }, {
      "heading" : "4. Bioavailability of phytochemicals",
      "text" : "The bioavailability is an important aspect that is studied in\npharmacology. Bioavailability literally means that the amount or\nfraction of the administrated drug that is absorbed to the systemic\ncirculation. The bioavailability of a drug depends upon the method\nof administration and the receiving individual [30]. Technically the\nbioavailability of a drug administered intravenously is hundred\npercentage, while the bioavailability of the drugs administered non-\nintravenously is found to degenerate due to poor absorption. In\ncase of other dietary supplements or medicinal herbs the\nbioavailability is very deprived when they are consumed orally [31].\nThe bioavailability of the phytochemicals present in the food we\nconsumed has been a critical factor that is extensively researched.\nManach et al., found that the bioavailability of dietary polyphenols\nis influenced by the absorption in the gut, microbiota metabolism,\nglucuronide excretion to the intestinal lumen, plasma kinetics, liver\nand gut metabolism, accumulation in tissues and bile, urinary\nexcretion and a variety of metabolites in the bloodstream, bonding\nto albumin, cell assimilation and metabolism [32]. The plasma\nconcentration of the various phytochemicals were calculated to\nstudy the complex bioavailability of them. For example, the\ncatechins are absorbed rapidly and supposed to be absorbed in the\nsmall intestine yet affected by the dimerization. The compounds\nlike epigallocatechin gallate and other catechin monomers are\nfound to have similar properties. Meanwhile, the flavanones are\nslowly absorbed due to the attached disaccharides. The highest\nbioavailability was seen in the isoflavones subclasses. In case of the\naglycones and the glucosides, the absorption was relaxed\nsuggesting the absorption from the colon part. The anthocyanins\nare quite rapidly absorbed, but their bioavailability seems to be the\nlowest of all flavonoids [33]. Similarly, the proanthocyanidins and\nhydroxycinnamic acids which is abundant in the human diet were\nalso not absorbed. The plasma concentrations of the isoflavones\nwas found to be 5 μmol / L whilst, the plasma concentrations for\nprocanthocyandins did not exceed 1 μmol / L. The bioavailability of\nthe phytochemicals is also influenced by the esterification process\n[34]\nFigure 3: Common routes of phytochemicals administration from food and nano-carriers\nFor the most part, the phytochemicals present in the plant foods\nare poorly absorbed by the human subjects, which is rapidly\nmetabolised and excreted. This is one of the major issue to be faced\nbefore implementing these phytochemicals against the war of\ncancer"
    }, {
      "heading" : "Phytochemical Chemical structure Major Source",
      "text" : "Apigenin\nParsley, Celery, Celeriac, Chamomile Tea\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n4 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nBerberine\nOregon Grape, Barberry, Tree Turmeric, Goldenseal, Yellow\nRoot, Amur Cork Tree, Chinese Goldthread, Prickly Poppy,\nCalifornian Poppy\nCombretastatin A-4\nEastern Cape South African bush-willow tree, Brazilian\nMofumbo\nCurcumin\nTurmeric\nEllagic acid\nNorth American white oak, European red oak, medicinal\nmushroom Phellinus linteus\nEmodin\nRhubarb, Buckthorn, Japanese Knotweed\nEpigallocatechin gallate\nWhite Tea, Green Tea, Black Tea, Apple Skin, Plums, Onions,\nHazelnuts, Pecans And Carob Powder\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 5\nFerulic acid\nCoffee, Apple, Artichoke, Peanut, Orange, Female Ginseng,\nFlaxseed\nGallic acid\nIndian gooseberry, Gallnut, Witch hazel, raspberry, North\nAmerican white oak, Sundew, Blackberry, Hot chocolate, Green\ntea\nGambogic acid\nBrownish or Orange resin of Indian Gamboge tree\nHonokiol\nIn the bark, seed cones, and leaves of trees belonging to the\ngenus Magnolia.\nβ-lapachone\nIn leaves and barks of Chinese catalpa\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n6 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nLuteolin\nRagweed pollen, Celery, Broccoli, Green Pepper, Parsley,\nThyme, Chamomile Tea, Carrots, Olive Oil, Peppermint, Navel\nOranges\nNoscapine\nIn all plant of plants of the poppy family\nNobiletin\nIn the peels of citrus fruits\nResveratrol\nIn the skin of Grapes, Blueberries, Raspberries, Mulberries\nSilibinin\nMilk thistle seeds\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 7\nThymoquinone\nin the plant Nigella sativa and Wild bergamot\nTriptolide\nThunder God Vine\nUrsolic acid\nApples, Basil, Cranberries, Elder Flower, Peppermint, Rosemary,\nLavender, Oregano, Thyme, Hawthorn, Prunes\nZerumbone\nGinger\nTable 1: Different types of phytochemicals and their sources\n. However, the drug delivery which involves nanocarrier has proven to increase the bioavailability of the drugs. Manzoor et al studied the bioavailability doxorubicin when delivered with nanoliposomes. The bioavailability of doxorubicin was improved by thermally sensitive liposomes release inside the tumor vasculature. The maximum penetration of free doxorubicin was limited to 34μm previously while this study depicted about 78μm diffusion distance in the both sides of the capillary bed in the tumor [35, 36]. Hence, the nano-drug delivery of the phytochemicals is thought to increase the possibility of the anticancer activity. The improved bioavailability during nanodrug delivery is the route by which the phytochemicals from food and nanocarrier reach cancer cells. The\nsame is diagrammatically given in figure 3.The anticancer effect of the nano-drug delivery of phytochemicals against various types of cancer is discussed in the further chapters.\nA particular study was done to overcome the limitation by\nManzoor et al. The bioavailability of doxorubicin was improved by thermally sensitive liposomes release inside the tumor vasculature. The maximum penetration of doxorubicin was limited to 34μm previously while this study depicted about 78μm diffusion distance in the both sides of the capillary bed in the tumor [25, 26]. Hence, the nano-drug delivery of the phytochemicals is thought to increase the possibility of the anticancer activity. The anticancer effect of the\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n8 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nnano-drug delivery of phytochemicals against various types of cancer is discussed in the further chapters."
    }, {
      "heading" : "5. Nano-drug delivery of phytochemicals against cancer:",
      "text" : "Despite the advanced treatment choices available for cancer patients, there is no particular method to cure cancer completely. This makes the scientist to continue their research on anticancer drugs and an effective way of administration. Above this, there are an enormous group of phytochemicals that have been proved to exhibit anticancer effect against different types of cancer. In order to enhance their minor backlogs, scientists employ the recently developed technique nanotechnology. It is a technology which manipulates matter with at least one dimension sized in nanometers. The completive nature of nanotechnology has made its application in number of science fields including organic chemistry, surface science, semiconductor physics, molecular biology, microfabrication, medicine, biotechnology etc. In almost all cases these application involve the usage of nanomaterials [37]. In particular the nanomaterial is used to build nano-system which vary in size between 1-100 nm and are employed as transport module to carry any other substance or drug in nanomedicine. This noanosystem may also be called nanocarrier [38]. There are different kinds of nanocarriers that are used to deliver drug in deadly diseases like cancer. The role of nanocarriers in cancer is inevitable as it plays a major part in both visualization and therapy. This is due to the fact that these nanocarriers can be easily fabricated to selectively target the cancer cells from normal cells [39]. Some of the main nanocarriers used in cancer are micelles, liposomes, dendrimers, carbon nanotubes, nanoshells and nanocages. The major principle involved in the manufacturing of some nanocarriers are diagrammatically depicted in figure 4. As shown in the diagram, the micelle is an aggregate of molecules with outer hydrophobic head region and hydrophilic tail region in the micelle centre. The dendrimer is a highly branched, star-shaped macromolecules with nanometer-scale dimensions that are symmetric around the core [40,41]. The liposomes are similar to micelle, it is a spherical vesicle where the hydrophilic and hydrophobic group are arranged to form a lipid bilayer. Nevertheless, the nanocomposite consists of multiphase materials with at least one of them in nano-dimension [42,43].\nAll these nanocarriers allow the delivery of hydrophobic and hydrophilic drugs throughout the body. As most of the human body contains water, this ability of the nanocarrier becomes a major therapeutic efficiency while the other is the targeted delivery of the drug [44]. The drugs carried are harmful to the normal cells present in the human body. The nanocarriers carefully deliver the drugs to the specific site due to their site-specificity and smaller size. The four type of targeting characteristics of a nanocarriers are passive, active, pH sensitivity and temperature sensitivity. The nanocarrier targets the delivery based on pH and temperature changes in cancer cells whereas it may also be cloaked in correspondence to the circulation time by coating materials like PEG. In case of active targeting the nanocarrier is provided with a cell specific ligand [45]. The foremost application of these nanocarriers is focussed on cancer chemotherapy. This may be because of the lower pH, higher temperature, hydrophobic nature of the anticancer drugs and potential need of specific target ability [46]. Another major advantage of nanocarriers in cancer is the enhanced permeability and retention (EPR) effect. It involves the aggregation of macromolecules or nanoparticles in the extravasation in the tumor tissue during angiogenesis or formation of new blood vessels. All the above factors make the application nanotechnology in cancer definite [47]. However, the major literatures on the nano-drug delivery of various phytochemicals against major cancers are enumerated in the consecutive subdivisions."
    }, {
      "heading" : "5.1 Lung Cancer",
      "text" : "Lung cancer is also known as pulmonary carcinoma which is characterized by uncontrolled cell growth in the lungs. It is one of the most common cause of cancer-related death in men and women. The major types of lung cancer include small-cell lung carcinoma, non-small-cell lung carcinoma and lung carcinoid tumor [48, 10]. The small-molecule polyphenol honokiol was found to have therapeutic effect against lung cancer. The honokiol was loaded to the micelles based on poly(ἐ-caprolactone)-poly(ethylene glycol)-poly(ἐ-caprolactone) copolymer (PCEC). The size of the obtained honokiol-loaded PCEC micelles was about 61nm. However, the particle size decreased in correspondence to the increase in temperature making it more suitable for drug delivery when injected via blood. Both the free honokiol and honokiol loaded micelles had a dose dependent antiprolierative effect on the A549 human lung adenocarcinoma cells and were comparable. The prepared micelles showed a typical two-phase-release profile in the in vitro condition [49]. Merlin et al., studied the anticancer effect of phenolic phytonutrient ferulic acid loaded poly-d,l-lactide-coglycolide (PLGA) nanoparticles on non-small cell lung carcinoma cell line. The ferulic acid loaded PLGA nanoparticles were prepared by double emulsion method and had a particle size of about 483 nm. The NCI-H460 cells were treated with ferulic acid alone as well as with the ferulic acid loaded PLGA nanoparticle. The results depicted an increased anticancer effect of ferulic acid loaded nanoparticle. Further, the nanoparticle induced cytotoxicity involved increase of reactive oxygen species (ROS) level, DNA damage, altered mitochondrial transmembrane potential (MMP) and apoptotic morphological changes. These factors suggest that ferulic acid loaded PLGA nanoparticle is a respectable therapeutic tool against lung cancer [50].\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 9\nThe novel anticancer drug β-Lapachone (β-lap) which is bioactivated by NAD(P)H:quinone oxidoreductase-1 (NQO1), an enzyme found specifically overexpressed in non-small cell lung cancer (NSCLC) was delivered using nanoparticles. The β-Lap was incorporated into poly(ethylene glycol)-co-poly(D,L-lactic acid) (PEG-PLA) polymer micelles using a film sonication procedure. The prepared micelles had a core-shell architecture and was about 30nm in size. β-Lap micelles were injected via the tail vein or caudal vein of mice with subcutaneous A549 lung tumors and the biodistribution was studied. The results showed that the prolonged blood circulation and increased accumulation of β-Lap. Additionally, the in vitro administration of the micelles LLC tumors led to the DNA damage and PARP-1 hyperactivation [51]. The basic principal involved in formation of polymeric micelles is illustrated in figure 5. Zhang et al., examined the combinational effect of β-Lapachone and paclitaxel micelles against A549 non-small cell lung cancer (NSCLC) cells. The co-encapsulation of β-Lapachone and paclitaxel in the PEG-PLA micelles had an encapsulation efficiency of 100.7 ± 2.2% and drug loading efficiency of about 100.3 ± 3.0%. The combinational β-Lapachone and Paclitaxel micelle was found to have more improved effect that the β-Lapachone micelle and Paclitaxel micelle alone. The combinational micelle had a significant antiproliferative effect at IC50 of 0.16 μM while the individual IC50 was 4.5 μM and 0.32 μM for β-Lapachone micelle and Paclitaxel micelle. Thus both the compounds were supposed to exhibit synergistic effect against lung cancer [52].\nFigure 5: Formation of polymeric micelles\nThe flavonoid luteolin was encapsulated in to a nanocarrier and tested against H292 lung cancer cells. The nanocarrier had a polymeric base, made up of ploylactic acid and polyethylene glycol (PLA-PEG). The formed nanoparticle had a mean size of about 115 nm. The luteolin loaded nanoparticle and free luteolin showed antiproliferative activity against H292 cells. The IC50 of nanoluteolin was significantly less than free luteolin, showing that the nanosystem contributes to improved bioavailability. Similar results were observed in the colony formation assay [53]."
    }, {
      "heading" : "5.2 Breast Cancer",
      "text" : "Breast cancer is a malignant tumor that starts in the cells of the breast and occurs commonly in women. Women around the age of 40 to 70 years are more prone to breast cancer. It ranks to be the second common cause of death worldwide and if left untreated easily spreads to other parts of body. The metastasis of breast cancer is often found to cause lung cancer in many cases [10, 48]. The diarylheptanoid compound curcumin was delivered using a biologically derived nanoparticle to the MCF-7 and MDA-MB-453 breast cancer cell lines and its therapeutic effects were recorded.\nThe nanoparticle was manufactured from covalently blended silk fibroin and chitosan (SFCS) polymers or silk fibrin polymer alone by the capillary-microdot technique. All the synthesized nanoparticle were less than 100 nm in size and was tested with the breast cancer cell lines. Interestingly, the silk fibroin showed higher uptake and efficacy than SFCS nanoparticle in both breast cancer cell line. The cell viability of the both breast cancer cell lines were decreased by the silk fibroin nanoparticle when compared to that of the SFCS nanoparticle [54]. Sebak et al., produced a nanoparticle from human serum albumin (HSA) for targeted delivery of noscapine and enumerated its response in SK-BR-3 breast cancer cells. Noscapine is obtained from plants of the poppy family and is a benzylisoquinoline alkaloid. The pH-coacervation method was employed to form HAS nanoparticle and noscapine loaded nanoparticle. The nanoparticle size ranged between 150-300 nm and had 85-96% of drug loading efficiency. About 10% of noscapine was released with the initial burst from the nanoparticle followed by a sustained drug release. The SK-BR-3 breast cancer cells were treated with the HAS nanoparticles as well as with the noscapine loaded HAS nanoparticle. Both the drug loaded and drug free nanoparticles reduced the viability of the breast cancer cells whilst the effect of noscapine loaded nanoparticles was significantly higher when compared [55].\nA pH-sensitive liposomes was used to deliver ursolic acid, a triterpenoid compound to the MDA-MB-231 breast cancer cells. The pH-sensitive liposomes was prepared by the lipid hydration method. The liposomes had a mean diameter of 191.1 ± 6.4 nm and a long term stability. The liposomes were predominantly of vesicle size less than 100 nm promising good drug loading efficiency. The MDA-MB cells were exposed to the pH-sensitive ursolic acid liposomes. The IC50 value of the ursolic acid liposomes were much lower than the free ursolic acid indicating the improved anticancer activity of the nano-liposomes [56]. Odeh et al., prepared two different kinds of liposomes, one thymoquinone-loaded liposomes (TQ-LP) and other thymoquinone loaded in liposomes modified with Triton X-100 (XLP). Thymoquinone is an herbal derived phytochemical which has excellent chemopreventive property and is hydrophobic in nature. Both the nanoparticles had a diameter of about 100 nm while the entrapment efficiency was more than 90% for TQ-LP and 49.6% for XLP. Their biological activity was studied using both MCF-7 cancer cells and fibroblast cells. However, the TQLP was effectively supressed the proliferation of MCF-7 cells and exerted very low toxicity on normal periodontal ligament fibroblasts [57].\nThe inhibitory effect of silibinin and d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) on the breast cancer cells was recorded. The silibinin-loaded lipid nanoparticles containing TPGS and phosphatidylcholine were designed and prepared by a thin-film hydration method. The nanoparticle was in the average size of 45 nm and the encapsulation efficiency of silibinin in the nanoparticle was 98.63±0.30%. The cellular uptake studies showed that the drug content in MDA-MB-231 breast cancer cells after silibinin nanoparticle treatment for 24 h was about twice as much as that after free silibinin treatment. Corresponding results were observed in the cell viability, invasion and migration assays. However, the silibinin loaded nanoparticle tremendously suppressed the invasive and migratory capabilities of MDA-MB-231 cells at a concentration of 20 µg/mL through the downregulation of MMP-9 and Snail pathways. Thus, it was concluded that the silibinin loaded TPGS\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n10 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nnanoparticle as a novel therapeutic agent against breast cancer [58]. Sharma et al., used the dendrimers to deliver the phenolic phytochemical gallic acid for inhibiting breast cancer cells. The dendrimers were made up of Polyamidoamine (PAMAM) using Tomalia’s divergent growth approach. The dendrimers provided high degree of surface functionality and versatility for the gallic acid loaded to it. The cytotoxicity of the gallic acid loaded PAMAMnanoparticle was found using the MCF-7 human breast cancer cells. The MCF-7 cells were treated with the PAMAM dendrimer, gallic acid and the gallic acid loaded-PAMAM nanoparticle. The IC50 values showed that the gallic acid loaded PAMAM nanoparticles had a synergistic antiproliferative effect on the growth of MCF-7 cells [59]."
    }, {
      "heading" : "5.3 Colorectal cancer",
      "text" : "Cancer that occurs in colon or rectum is termed as colorectal cancer. It ranks to be the third most common type of cancer as the American Cancer Society's estimates 136,830 new cases and 50,310 deaths due to colorectal cancer in the United States for 2016. It is more susceptible to the diet we consume as the colonic epithelial cells come in direct contact with them [10, 48]. Zheng et al., recorded the cytotoxicity of triptolide and triptolide loaded polymeric micelles against HT29 human adenocarcinoma cells. Triptolide is a diterpenoid tri-epoxide purified from the Chinese herb Tripterygium wilfordii which has anticancer property but exhibits some other side effects. The triptolide loaded polymeric micelles (TP-PM) was synthesized using the methoxypoly(ethylene glycol)-poly lactic acid (MePEG-PLA) copolymer by a solvent evaporation method. Both the free triptolide and the TP-PM had a dose- and time dependent effect on the HT-29 cells, however the inhibitory effects of TP-PM on the tumor cell growth were more significant for all incubation times and concentrations. In addition to this the incubation of HT29 cells with triptolide and the TP-PM also depicted increase in the caspase 3/7 activity indicating apoptosis with the highest apoptosis index at 6.96 after 48 h incubation with 10 ng/ml TP-PM. Hence, the polymeric micelles served as an excellent carrier of TP and reduced its toxicities [60]. The small-molecule polyphenol compound honokiol was loaded into the self-assembled biodegradable star-shaped micelles and tested for chemotherapeutic effects. The biodegradable polymeric micelles was made up of the monomethoxy poly (ethylene glycol) (MPEG) and poly (ἐ-caprolactone) (PCL) and loaded with the honokiol by direct dissolution method assisted by ultrasonication. The average particle size of obtained honokiol micelle was about 40nm and was treated to CT26 murine colon carcinoma cells. The release rate of honokiol from the star-shaped polymeric micelles was slower. Nevertheless, they exhibited antiproliferative effect against the CT26 cells in a dose dependent fashion. Therefore, this star-shaped honokiol micelle may be used to design a new dosage form [61].\nRavindran et al., studied anti-proliferative property of the bioactive phytochemical Nigella sativa, thymoquinone loaded in poly (lactideco-glycolide) (TQ-PLGA) nanoparticles using human colon cancer HCT 116. The TQ-PLGA nanoparticle had an encapsulation efficiency around 94% and ranged between 150 and 200 nm in size. The TQPLGA nanoparticle had an effective anticancer against the HCT116 cells. Apart from this the nanoparticles were active in inhibiting NFkB activation and in suppressing the expression of cyclin D1, matrix\nmetalloproteinase (MMP)-9, vascular endothelial growth factor (VEGF) when compared to the free thymoquinone. On the whole, the results demonstrate that encapsulation of TQ into nanoparticles enhances its anti-proliferative effects [62]. Luteolin (Lu), is a flavonoid with anticancer activity but it said to have poor water solubility. It was delivered by the monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL) micelles in vivo condition to evaluate the biodistribution and to the C-26 colon carcinoma cells to find their anticancer property. The MPEG-PCL micelles encapsulated Lu by a self-assembly method. Fabricated Lu/MPEGPCL micelle was water-soluble with the approximate size of about 38.6 nm and encapsulation efficiency of about 98.32%. The pharmacokinetics of free luteolin and Lu/MPEG-PCL micelles was studied in rats suggest that the bioavailable concentration of luteolin was more when the Lu/MPEG-PCL micelles were used. Further, the Lu/MPEG-PCL micelles inhibited the growth of C-26 colon carcinoma cells at IC50 of 12.62 ± 2.17 μg/mL. Hence, the study recommends that encapsulation of Lu into MPEG-PCL micelles created an aqueous formulation of Lu with potential anticancer effect [63].\nZhang et al., enlisted the effects of self-carried curcumin nanoparticles for in vitro and in vivo colon cancer therapy. The curcumin nanoparticle was prepared by the re-precipitation method and then was anchored to the poly(maleic anhydride-alt-1octadecene)-polyethylene glyco (C18PMH-PEG) on the surface by ultrasonication to improve the biocompatibility of the nanoparticles. The nanoparticles had loading efficiency of about 78.5%, encapsulation efficiency of about 95.8% and displayed a sustained release behaviour without any initial burst. The curcumin nanoparticles were tested for its anticancer property with the CT-26 colon cancer cells. The results showed that the curcumin nanoparticles had an 8-fold decrease in the half-maximal inhibitory concentration (IC50) values of the free curcumin (IC50 = 33.4 μM) compared to the curcumin nanoparticles (IC50 = 4.2 μM). Analogous results were seen in the in vivo testing. After administration of the curcumin and curcumin nanoparticle to the CT-26 tumor-bearing nude mice, the tumor volumes were 87% and 32% respectively. This shows that the curcumin nanoparticle has more effect that free curcumin on the tumor cells. However, the curcumin nanoparticle had no adverse or toxicity when investigated for in vivo systemic toxicity [64]."
    }, {
      "heading" : "5.4 Skin cancer",
      "text" : "Skin cancer is the most common form of cancer, globally accounting for at least 40% of cases and is especially common among people with light skin. The most dangerous type of cancer is the one which occurs in the melanoma or the cells which contains melanocyte pigments. The exposure to the ultraviolet radiation emitted by the sun is said to be a major cause of cancer [10, 48]. Das et al., extensively studied the effects of the flavone apigenin against melanoma when delivered using poly (lactic-co-glycolide) nanoparticles. The apigenin loaded poly (lactic-co-glycolide) nanoparticles was prepared by the solvent displacement method. The prepared nanoparticle demonstrated a biphasic release profile, showing an initial burst followed by a controlled release for 3 days. The anti-proliferative effect of the nanoparticle was examined with A375 skin melanoma and HaCaT keratinocytes. It was observed that the nanoparticle had a dose dependent effect on the A375 cells\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 11\nwith the IC50 of 15 µM when the apigenin alone had an IC50 of 25 µM. In contrast, there was no cytotoxic effect on the normal HaCaT cells. The nanoparticle induced the intercalation of double-stranded DNA (dsDNA) along with the increase in ROS accumulation and depletion of the antioxidant enzyme activities, mediating apoptosis through mitochondrial dysfunction [65]. This was followed by the study on anti-carcinogenic effect of the apigenin loaded poly (lacticco-glycolide) nanoparticles against ultra-violet B (UVB) and Benzo(a)pyrene (BaP) induced skin tumor in mice. Along with the anti-carcinogenic effect the changes in the mitochondria was also studied after apigenin deliverey. The apigenin loaded nanoparticle showed better results against UVB–BaP induced melanoma, which may be related to the smaller size and faster mobility. The nanoparticles decreased the tissue damage as well as the frequency of chromosomal aberration. Apart from this there was increase in the ROS generation, mitochondrial matrix swelling and modulation of the apoptotic markers such as Apaf-1, bax, bcl-2 and cyt c. Thus, the apigenin loaded poly (lactic-co-glycolide) nanoparticles possess potential ability for therapeutic management of skin cancer [66].\nIn yet another study the dihydrostilbenoid, combretastatin A-4 was co-encapsulated with doxorubicin and tested for anticancer property in both in vitro and in vivo condition. The compounds were loaded to the RGD-modified liposomes. The cellular uptake of doxorubicin by the integrin-overexpressing B16 and B16F10 melanoma cells was improved by the disrupting agent combretastatin A-4. Moreover the co-encapsulated liposomes were more toxic towards the melanoma cells than the doxorubicin loaded liposomes. Similarly, the combretastatin A-4 and doxorubicin loaded liposomes exhibited the most pronounced tumor regression effect in the male C57BL/6 mice inoculated melanoma B16F10 cells. Thus, the combretastatin A-4 encapsulation improved the efficacy of the doxorubicin [67]. Siddiqui et al., recently studied the anti-proliferative and proapoptotic effects of epigallocatechin 3-gallate (EGCG) encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo conditions. The EGCG was loaded to the nanoparticle made up of polylactic acid-polyethylene glycol nanoparticles in order to enhance the bioavailability of it to the melanoma cells. The Mel 928 cells were used to test the effects of EGCG loaded nanoparticle and free EGCG. The results showed that there was about 8-fold dose advantage of this nano-formulation over native EGCG in retarding the growth of melanoma cells. Further, the growth of Mel 928 tumor xenograft in the mice model was observed when EGCG-loaded nanoparticle was given. This inhibition included cell cycle phase arrest, changes in the level of cyclins D1 and D3 protein expression [68]."
    }, {
      "heading" : "5.5 Ovarian Caner",
      "text" : "Ovarian cancer occurs when there is an uncontrolled growth of cells in the ovary. The women who have ovulated more over their lifetime and those who have never had children are more vulnerable to ovarian cancer. According to the statistical reports, about 14,240 women will die from ovarian cancer in US alone and death from ovarian cancer is more common in North America and Europe than in Africa and Asia [10, 48]. The small-molecule polyphenol honokiol was loaded to a nanoparticle and was delivered to the ovarian cancer cells in the laboratory condition. The nanocarrier was manufactured with the monomethoxy\npoly(ethylene glycol)–poly(lactic acid) (MPEG–PLA) by the ring opening polymerization method and then honokiol compound was loaded to it by solvent extract method. The honokiol-loaded MPEGPLA nanoparticle had a spherical appearance with the mean particle size of ca. 80 nm. The nanoparticle was found to release 53% within 24 h in the laboratory condition. Both the free honokiol and honokiol loaded MPEG-PLA decreased the viability of the A2780 human ovarian cancer cells with increasing concentration. However, the honokiol loaded MPEG-PLA nanoparticle potentially inhibited the growth of A2780 cells at the IC50 was 8.45µg/ml. This was greater than the effect than the free honokiol [69]. Yallapu et al., studied improved therapeutic effects of curcumin loaded to the poly(lactic-co-glycolide) (PLGA) nanoparticle and its anti-cancer effect against the cisplatin resistant A2780CP ovarian cancer cells. Fabricated nanoparticle was found have an average size of 560.4 nm and had a sustained and controlled drug release of curcumin in the in vitro condition. The curcumin-loaded PLGA nanoparticle inhibited the growth of the A2780CP cells at an IC50 of about 13.9l M which was superior when compared to the effects of free curcumin. Similar results were seen in the long term effect examination and the curcumin loaded PLGA nanoparticle reduced the number of cancer cells in the colony. These results suggest that the curcumin loaded PLGA nanoparticle as one of the ideal therapeutic agent [70].\nThe anticancer activity and molecular mechanism of resveratrolbovine serum albumin nanoparticles (RES-BSANP) on subcutaneously implanted human primary ovarian carcinoma cells in nude mice was examined in the recent years. The tumor was induced by injecting the SKOV ovarian cancer cells into the nude mice and were given 200, 100, and 50 mg/kg RES-BSANP or 0.5 mL RES once a week. The tumor progression observation showed that the RES-BSANP significantly retarded the growth of carcinomas in nude mice from the third week onwards, and the inhibition rate was markedly higher than in mice treated with RES. The RES-BSNAP was found to induce apoptosis by releasing the cytochrome c and regulating the caspase-3, 9 and thereby indicating mitochondrial apoptotic pathway [71]. The hydrophobic drug curcumin was encapsulated in to the hydrophilic polymeric core and delivered to the SKOV-3 ovarian cancer cells. The hydrophilic polymeric core was made up of poly(2-hydroxyethyl methacrylate) [PHEMA] nanoparticles. After the loading the curcumin the nanoparticle had a size of about 300nm. The in vitro investigations showed that the curcumin loaded nanoparticle showed better tumor cells regression activity than free curcumin. Further, they also showed notable decrease in the G0/G1 phase cells. These nanosystems which delivered curcumin showed excellent biocompatibility when studied with zebrafish embryo model [72]."
    }, {
      "heading" : "5.6 Prostate Cancer",
      "text" : "The malignant growth of cells in the prostate gland of the male reproductive organ leads to prostate cancer. As the cancer develops in the glands, they are medically termed as adenocarcinoma. According to the estimation of American cancer society, about 180,890 new cases of prostate cancer are expected in 2016 which means 1 in 7 American men will be diagnosed with prostate cancer [10, 48].The gallic acid ester derivative, epigallocatechin 3-gallate (EGCG) was delivered to the prostate cancer cells by a biodegradable nanoparticle. Here, EGCG was combined with the\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n12 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\npolylactic acid-polyethylene glycol polymeric profiles along with the prostate-specific membrane antigen (PSMA) targeting ligands. The pseudomimetic dipeptideN-[N-[(S)-1,3-dicarboxypropyl]carbamoyl](S)-lysine (DCL) was the PSMA targeting ligand. The antiproliferative effect of the targeted nanoparticle as well as the nontargeted nanoparticle on the LNCaP androgen-sensitive human prostate adenocarcinoma cells. The experimentation with both the nanoparticles were exposed to PCa prostate cancer cells. The growth inhibition exhibited by EGCG loaded nanoparticle possessed high efficacy and target specific. Apart from this the EGCG loaded nanoparticle was found to be ineffective in inhibiting HUVEC proliferation. Thus the developed nanoparticles proved to exhibit selective toxicity against prostate cancer [73]. Zu et al., evaluated the enhanced targeting ability of the folate mediated EGCG bovine serum albumin nanoparticles (FA-EGCG-BSANP) nanoparticle against PC-3 prostate cancer cells. The nanoparticle was prepared by the desolvation method and possessed a mean particle size of about 200 nm with the entrapment efficiency of about 81.5%. The folate mediated nanoparticle was found to have concentration dependant targeting to the PC-3 cells. The PC-3 cells uptake of FAEGCG-BSANP was 23.65 times than that of the EGCG-BSANP. The folate present in the nanoparticle was found to improve the lethality of PC-3 cells due to FA-EGCG-BSANP [74].\nIn yet another experiment the gallate EGCG was delivered to the prostate cancer cells using a nanocarrier and its results were recorded. The nanocarrier was made up of polylactic acid– polyethylene glycol (PLA-PEG) and was tested in in vivo as well as in vitro condition. The effect of nano-trapped EGCG was 10-fold higher than the free EGCG when given the PCa prostate cancer cells. The IC50 was measured to be 3.74 μmol/L for the EGCG loadednanoparticle and there was significant increase in pro-apoptotic Bax with a concomitant decrease in anti-apoptotic Bcl-2 in the PCa cells. The 22Rν1 cells were injected to the mice and then were given EGCG loaded- nanoparticle as well as free EGCG. The outcome was alike to that of the in vitro conditions and the tumor size was reduced significantly [75].\nFigure 6: Extraction and loading of curcumin\nBesides the gallate, the yellow polyphenol curcumin was also explored for its anticancer property. Mukerjee et al., developed a curcumin loaded nanoparticle and investigated its anticancer property against the prostate cancer cell lines LNCaP, PC3 and DU145. Curcumin was loaded to the poly (lactic-coglycolic acid) (PLGA) nanospheres prepared by solid/oil/water emulsion solvent evaporation method. The prepared nanospheres were found to have a mean size of about 45 nm with a biphasic drug release manner. The curcumin loaded PLGA nanospheres was found to be more effective than that of the free curcumin. This was reflected in the half-maximal inhibitory value. The IC50 of curcumin loaded PLGA nanospheres ranged between 20 μM-22.5 μM while that of\nfree curcumin ranged from 32 μM to 34 μM. Besides this the curcumin loaded PLGA nanospheres also highly inhibited NF-κB function when compared to free curcumin [76]. In yet another study of anticancer effect of nanoemulsion of curcumin in combination of resveratrol, the natural phenol in the nanoparticle was done. Separate nanoemulsions containing the liposomes loaded with curcumin and liposomes loaded with resveratrol was prepared and co-administered to the PTEN-CaP8 cancer cells and PTEN knockout mice with prostate cancer. The in vitro studies showed that the curcumin with resveratrol effectively inhibit cell growth and induced apoptosis. In addition to this the combination also significant repressed the expressions of p-Akt, AR, cyclin D1 and mTOR proteins in PTENCap8 cells with loss of PTEN. Similarly, the mice which was given the combination (25 mg/kg) had a positive response than the mice administered with either lipocurcumin or lipo-resveratrol (50 mg/kg each) for 7 weeks. A notable reduction in the prostate weight in the combination treatment group confirmed the decrease in the incidence of mouse prostatic intraepithelial neoplasia (mPIN) lesions. Apart from these the availability of curcumin was improved during the co-administration of lipo-curcumin and lipo-resveratrol [77]. A diagrammatic representation of extraction as well as loading of curcumin is given in figure 6."
    }, {
      "heading" : "5.7 Cervical Cancer",
      "text" : "Cervical cancer is a cancer arising from the cervix, a part of uterus. In 90% of the cases cervical cancer is found to occur due to the Human papillomavirus (HPV) infection. It ranks to be the fourth most common cause of death from cancer in women, globally. However, cervical pre-cancers are diagnosed far more often than invasive cervical cancer [10, 48]. A fluorescence study of the curcumin-casein micelle complex and its application as a drug nanocarrier to cancer cells was done by Sahu et al. The curcumin was loaded to the bovine casein micelles and the prepared micelles were less than 200 nm with a roughly spherical shape. These curcumin-micelles were formed due to the hydrophobic interactions between the casein micelles and curcumin. The HeLa cervical cancer cells were used to study the cellular uptake and toxicity of free curcumin and curcumin-casein micelles. From the green fluorescence emitted after the treatment showed that the casein micelles has improved the uptake of the curcumin. The cellular uptake was in a concentration-dependent increase. Similar, results were obtained from the cytotoxicity studies and the IC50 of free curcumin and the CM-curcumin complex was 14.85 and 12.69 μM, respectively. This showed that the casein micelles proved to be a good drug carrier [78]. Das et al., loaded the yellow phytochemical curcumin to alginate-chitosan-pluronic composite nanoparticles for delivering it to the HeLa cancer cells. The nanocomposite particle were created with the alginate, chitosan and pluronic using the ionotropic pre-gelation and polycationic cross-linking. The pluronic was used to improve the solubility of curcumin which was verified in the encapsulation efficiency studies. The nanoparticles were in the average size of about 100 nm. The drug release from the nanoparticle was in a controlled manner and the cellular uptake was respectable in the HeLa cells. Apart from this the cell viability of HeLa cells were significantly decreased by the curcumin loaded composite nanoparticle at a concentration of 500 μg/mL [79].\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 13"
    }, {
      "heading" : "5.8 Liver cancer",
      "text" : "Liver cancer, often referred as hepatic cancer is a cancer that originates in the liver. It is usually diagnosed accidentally and mostly occurs due to cirrhosis which is due to due to either hepatitis B, hepatitis C, or alcohol. About 39,230 new cases are estimated to be diagnosed by the American cancer society in 2016 for liver cancer [10, 48]. Lin et al., investigated the effect of berberine, a form of isoquinoline alkaloids, in the liposomal form against hepatoma. The berberine liposome was manufactured by the thin-film hydration/extrusion method and has a 5 % mol polyethenyl glycol (PEG). The berberine liposome had an encapsulation efficiency of 14% and were exposed to HepG2 liver hepatocellular carcinoma cells. The berberine liposomes exhibited 2.5 times more toxicity against the HepG2 cells than that of the berberine solution. The berberine liposome significantly inhibited the growth of HepG2 cells at 1.67 µg berberine/mL and induced apoptosis through the caspase/mitochondria-dependent pathway. Further, the liposome was tested in the in vivo condition in nude mice bearing the HepG2 tumor. The results showed that the berberine liposomes effectively reduced the size and weight of tumor growth along with the reduction in the rate of elimination of berberine in both plasma and tissues. Therefore, the work demonstrated that the liposome was a good carrier for the berberine [80].On the other hand the same phytochemical was delivered as nanosuspension to the human hepatocytes HepG2 and Huh7 cells. The nanosuspension consisted of the berberine phytochemical and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) with an average size of 73.1 ± 3.7 nm. The nanosuspension had significant effect on the growth of HepG2 and Huh7 cells at a concentration of 8.1 and 4.7 μg/ml. In contrast the free berberine supressed the growth of the hepatoma cells at 18.3 and 6.5 μg/ml (HepG2 and Huh7 cells respectively). In the in vivo experiment with H22 solid tumor bearing mice, the berberine nanosuspensions had an inhibition rate of 63.7% while the free berberine had only 41.4 %. Thus the nanosuspension has improved the availability of the phytochemical to the cancer cells [81].\nStudies were done to record the effect of a xanthonoid, gambogic acid loaded in the lactoferrine nanoparticles against cancer. The lactoferrine is a cationic iron-binding glycoprotein and the gambogic acid-lactoferrin nanoparticles (GL-NPs) were produced by the nanoparticle albumin-bound (NAB) technology. The GL-NPs had a mean size of about 150 nm and an encapsulation efficiency of 7.2% and the in situ intestinal perfusion displayed a good absorption of the gambogic acid from the GL-NPs. The GL-NPs showed almost an identical antiproliferative effect in the HepG2 liver carcinoma cells to that of the arginine solution of gambogic acid. Apart from this the GL-NPs exhibited a high inhibitory rate when orally administered to the S180 tumor mice and controlled the tumor growth. This was about 1.39-folds higher than the effect of arginine solution of gambogic acid. These obtained research works have also paved the preliminary way for the study of lactoferrine as an oral drug delivery carrier [82]. Zhai et al., prepared an apigeninloaded polymeric micelles and tested its antiproliferative effect against HepG2 liver carcinoma cells. The polymeric micelles were composed of Pluronic P123 and Solutol HS 15 with an average diameter of 16.9 nm. They had an entrapment efficiency and drug loading was 96.36% and 1.32%, respectively. Around 84% of the apigenin was delivered by the polymeric micelles displaying a\nsustained drug release behaviour. The IC50 values on HepG2 cells for apigenin-loaded polymeric micelles and free apigenin solution were 5.57 µg/mL and 20.19 µg/mL, respectively. The growth of HepG2 cells was significantly reduced by the apigenin micelles at lower concentrations than the free apigenein, which may be related to its improved hydrophilic characteristics [83].\nThe diarylheptanoid compound curcumin was conjugated to the gum Arabic and was used against hepatoma cell lines. The gum Arabic is a highly polysaccharide substance which is used to improve the solubility of curcumin. The self-assembled conjugates had a spherical structure and a mean size of 270 nm. When tested the formed curcumin conjugate had improved solubility and stability of curcumin in physiological pH. Apart from this the curcumin conjugated retarded the growth of the HepG2 hepatocellular carcinoma cells. They also exhibited higher targeting ability toward the cells due to the galactose groups present in gum Arabic [84]. Beside the berberine nanosuspensions, resveratrol nanosuspensions were also prepared recently. The resveratrol nanosuspension contained resveratrol and poloxamer 188 and were manufactured using high pressure homogenization technique. The average size of the nanosuspension was 159 nm and vas evaluated for its effect on HepG2 cells along with free resveratrol. The results of MTT assay showed that the resveratrol inhibited the proliferation of HepG2 cells at IC50 2.91 μg/mL. In contrast the free resveratrol had similar effect only at 7.13 μg/mL. Hence, these results suggest that the delivery of resveratrol nanosuspension as a promising approach for treating tumors [85]."
    }, {
      "heading" : "5.9 Pancreatic cancer",
      "text" : "Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, hence mostly termed as pancreatic adenocarcinoma. It ranks to be seventh most common cause of death with about 40,560 deaths predicted in 2016 alone. It is usually due to usage of tobacco and obesity [10, 48]. The polyphenol curcumin was explored for its anticancer property against pancreatic cancer. The nanocurcumin or the curcumin encapsulated nanoparticle was synthesised using the micellar aggregates of cross-linked and random copolymers of Nisopropylacrylamide (NIPAAM), with N-vinyl-2-pyrrolidone (VP) and poly(ethyleneglycol)monoacrylate (PEG-A). The developed nanocurcumin was found to readily disperse in the aqueous medium displaying the hydrophilic nature. Nevertheless the MiaPaca pancreatic cancer cell line was treated with curcumin and nanocurcumin. Both of them significantly suppressed the growth of pancreatic cancer cells at 10 and 15 μM respectively. Further the nanocurcumin obstructed the activation of nuclear factor kappa B (NFκB), downregulated the IL-6, IL-8, and TNFα cytokines thereby inducting cellular apoptosis. Thus it was found that the nanocurcumin possessed all the properties of curcumin with better solubility [86]. Wei et al., entrapped the phytochemical curcumin as an ester to cholesteryl-hyaluronic acid (CHA) nanogel and was employed in the targeted delivery to CD44-expressing drugresistant MiaPaca cancer cells. The curcumin conjugated nanoparticle was 20 nm in diameter with a spherical structure. The gastrointestinal stability studies showed that the curcumin loaded nanoparticle was absorbed in the gastrointestinal tract and then entered the blood circulation. Thus, it was concluded that the oral administration of the nanoparticle with curcumin would lead to 2-\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n14 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\n5% loss. Apart from this the nanoparticle induced apoptosis in cancer cells, suppressing the expression of NF- κB, TNF-α, and COX2 cellular targets similar to free curcumin. Moreover the curcumin loaded nanoparticle supressed the tumor growth up to 13-fold tumor in the 4T1 mice model injected with the MiaPaca cells. Hence, the nano-drug delivery of curcumin is found to be one of the ideal therapy for cancer [87].\nKesharwani et al., produced a parenterally administrable nanomicelles of 3,4-difluorobenzylidene curcumin (CDF) for treating pancreatic cancer. The 3,4-difluorobenzylidene curcumin is nontoxic analogue to the curcumin known for its high anti-cancer activity and improved pancreas specific accumulation in vivo, compared with curcumin. The nano-micelle was prepared by selfassembling the styrene-maleic acid copolymer (SMA) with CDF using the non-covalent hydrophobic interactions. They were found to have a sustained drug release behaviour when exposed to MiaPaCa-2 and AsPC-1 pancreatic cancer cell lines. The free CDF and the SMA-CDF nanomicelle showed toxicity against both the cell lines and the effect of nano-micelle was superior to the free CDF. The IC50 was calculated as 230 ± 4.68 nM for MiaPaCa-2cells and 710 ± 3.81 nM for AsPC-1 cells [88]. In addition to this, the same research group evaluated the response of CDF loaded to the hyaluronic acid-conjugated polyamidoamine dendrimers given to the CD44 overexpressing MiaPaCa-2 pancreatic cancer cells. The nanocarrier was made of poly(amidoamine) (PAMAM) and hyaluronic acid (HA) as a targeting ligand and then loaded with the CDF (HA-PAMAM-CDF). The whole dendimer system had a particle size of 9.3 ± 1.5 nm. They displayed a dose dependent cytotoxicity against the MiaPaCa-2 and AsPC-1 human pancreatic cancer cells. The half-maximal value was found to have 1.71 fold increase when provided with the presence of HA-ligand. However, the developed nanocarrier was found to be an excellent therapeutic device against CD44 overexpressing pancreatic cancer [89]."
    }, {
      "heading" : "5.11 Oral cancer",
      "text" : "Any cancerous growth witnessed in the oral cavity is generally termed as oral cancer. Usually it arises as a primary lesion in any of the tissues in the mouth, which gradually spreads. Oral cancer is twice common in men than in women and American cancer society estimated 9,450 deaths due to it in 2016 [10, 48]. Dihydroartemisinin (DHA), the active metabolite of Artemisinin was loaded a co-polymeric micelle and delivered to the oral cancer cells in laboratory condition. The co-polymeric micelles were made up of methoxy poly(ethylene glycol)/poly(L-lactic acid) (mPEG) and loaded with the DHA using the modified solvent evaporation method. The physicochemical observations revealed that the nanoparticles were stable, spherical in shape and had a mean size of about 130 nm. The release of DHA from the co-polymeric micelles were pH dependent and had a biphasic drug release behaviour, with an initial burst followed by a slightly fast drug release. The MTT assay showed that the DHA delivered from the micelle had a superior anticancer effect on the KB human oral cancer cells as the IC50 was found to be 18.70 µM while the free DHA was 24.55 µM. This showed that the nano-drug delivery improved the availability of the drug delivered. Besides the DHAmicelles treated cells showed some physical signs of apoptosis [90]. In recent year, the polyphenolic compound ellagic acid was encapsulated in the chitosan nanoparticle was delivered to the KB\nhuman oral cancer cell line. The ellagic acid was entrapped in to the chitosan nanoparticle using the ionic gelation method. The nanoparticles were found to have a spherical shape and an average size of about 176 nm. Further, the drug encapsulation efficiency was around 94% while the loading efficiency was 33% and the nanoparticle was found to have a sustained drug release behaviour. The ellagic acid was found to have a better therapeutic competence when delivered using the chitosan nanoparticle against the KB cells. They exhibited a dose-dependent effect and had an IC50 value of 0.953 µg/ml along with visible DNA fragmentation in the KB cells [91]."
    }, {
      "heading" : "5.12 Leukemia",
      "text" : "Leukemia, is a group of cancers that usually begin in the bone marrow and result in high numbers of abnormal white blood cells. It is common among the children in the developed countries and about 24,450 deaths were estimated by the American cancer society [10, 48]. Anand et al., investigated the antiproliferative activity of curcumin loaded PLGA nanoparticles in laboratory condition as well as the improved bioavailability in this method by in vivo examination. The curcumin drug was loaded to the polymeric based nanoparticle made up of poly (lactide-co-glycolide) (PLGA) and a stabilizer polyethylene glycol (PEG) with 97.5% encapsulation efficiency. Then the KBM-5 human chronic myeloid leukemia cells was exposed to the curcumin loaded PLGA-PEG. It was found that the curcumin loaded nanoparticle had improved cellular uptake, inhibition of TNF-induced NF-κB activation, suppression of NF-κB-regulated proteins involved in cell proliferation (cyclin D1), invasion (MMP-9), angiogenesis (VEGF) and induced apoptosis then free curcumin. In case of the mice, the 2.5 mg/kg of curcumin nanoparticle was injected intravenously. The HPLC analysis showed the curcumin nanoparticle was more bioavailable and had a longer half-life than free curcumin [92]. In another study the co-formulation of Doxorubicin and Curcumin in poly- (D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 Chronic myeloid leukemia cells. The doxorubicin and curcumin loaded PLGA nanoparticle was prepared by the single emulsion solvent evaporation technique with encapsulation efficiency of 46% and 86% respectively. When treated to the K562 cells the cellular uptake of dual drug loaded NPs was nearly ∼8 times higher than the dual drug in solution. Apart from this the nanoparticles exhibited significant growth inhibition at an IC50 value of 0.1 μg/mL when the nanoparticle administered in equivalent concentrations along with the gradual decrease in the expressions of MDR1 and BCL-2 at the mRNA level. Overall, this combinational strategy has noteworthy promise than that of the drugs alone [93].\nWang et al., studied the antileukemia mechanism of the multifunctional Chinese traditional medicine Emodin when conjugated to the D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) to form liposomes. The liposomes had a high encapsulation efficiency of about 95.2% ± 3.0% and had a particle size of 121.1 ± 44.9 nm. The emodin-TPGS liposomes were found to have an increased cytotoxicity on the L1210 and K562 leukemia cell lines. This cytotoxicity included the regulation of protein levels of myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma-2 (Bcl-2) and Bcl2-associated X (Bax). The bio-distribution study showed that the emodin-TPGS liposomes improved the bioavailability of emodin 1.7\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 15\ntimes higher than that of the free emodin in lungs and kidney [94]. The antiproliferative activity of a citrus polymethoxylated flavone nobiletin-loaded chitosan nanoparticles was recorded in parallel. The nobiletin-loaded chitosan nanoparticles was formed via Schiffbase formation and had a loading efficacy of 7.0%. The in vitro experiment was carried out using the RAW264.7 Abelson murine leukemia virus-induced tumor cell lines and L-929 normal subcutaneous connective tissue at various time intervals. It was found that both the raw nobiletin as well as the nobiletin-loaded chitosan nanoparticles suppressed the growth of RAW264.7 cells while not affecting the growth of L-929. Moreover the nobiletinloaded chitosan nanoparticles showed considerable inhibition at IC50 of 8 μg/mL of cancerous cells, revealing their great potential for applications in cancer chemotherapy [95].\nRahman et al., studied the antileukemic effect of a natural dietary lipophilic compound when loaded to the nanostructured lipid carriers. The zerumbone-loaded nanostructured lipid carriers were formed by high-pressure homogenization technique. The obtained ZER-NLC particles had an average size of 52.68 ± 0.1 nm and a drug loading efficiency of about 7.92%.the drug release of zerumbone from ZER-NLC was about 46.7% over 48 hours. When treated with the Jurkat acute lymphoblastic leukemia cells, the ZER-NLC significantly inhibited the growth with IC50 of 5.64 ± 0.38 μg/mL. Thus, the study suggests the ZER-NLC as a sustained-release drug carrier system for the treatment of leukemia [96]."
    }, {
      "heading" : "5.13 Cancer in nervous system",
      "text" : "The occurrence of cancer in the nervous system is a very rare scenario and affects the nervous system, such as brain cancer and sarcomas of the nerves [48]. The growth inhibition effect of resveratrol when delivered by a biodegradable nanoparticle was studied by Shao et al. The biodegradable nanoparticle was made up of mPEG-PCL and the resulting nanoparticle has a smooth spherical shape. The drug loading efficiency was about 19% while the encapsulation efficiency was 91% for the mPEG-PCL nanoparticles. They were tested against the C6 glioma cells. Glioma is a tumour which starts from brain or spin and from the glial cells. The resveratrol loaded nanoparticle exhibited greater cytotoxicity than the free resveratrol. Furthermore, the amount of ROS generated by the C6 cells when exposed to the resveratrol loaded nanoparticle was comparatively more. Hence, this study suggest that Res-loaded nanoparticles could be a potential chemotherapeutic formulation for malignant glioma therapy [97]. The curcumin phytochemical which has capacity to inhibit the beta amyloid is investigated for its ability to retard the growth of SH-SY5Y neuroblastoma cells. Neuroblastoma is an extracranial solid cancer growth composed of neuroblasts, most commonly in the adrenal gland. The curcumin was loaded to apolipoprotein E3 mediated poly(butyl) cyanoacrylate nanoparticles and had a particle size of around 195 nm. Moreover, the cell viability studies showed an enhanced therapeutic effect on the neuroblastoma cells with a sustained drug release effect. Similar to the anticancer activity of curcumin, the developed nanoparticles induced ROS generation, sub G1 cell cycle phase arrest along with induction of caspase-3. Hence they concluded that the curcumin loaded nanoparticles induced apoptosis in the SH-SY5Y cells [98].\n5.14 Other cancers:\nSou et al, studied the cytotoxicity of self-organized assemblies of curcumin micelles against the myeloma cells. Myeloma is a malignant tumour that occurs in the bone marrow cells known as plasma cells. The lipophilic drug curcumin was loaded to the amphiphatic poly(oxyethylene) cholesteryl ether (PEG-Chol) to form micelles. The curcumin loaded PEG-Chol nanoparticle possessed more cytotoxicity against the myeloma cells. The viability of the myeloma cells was significantly decreased by the curcumin-loaded PEG-Chol nanoparticle at 1 µM while the free curcumin had significant effect at 5 µM. Hence, the PEG-Chol nanosystem seems to allow stable drug carrier for curcumin [99]. The hydrophobic ursolic acid is able to induce cell death when delivered to the SGC7901 gastric cancer cells using nanoparticle. Gastric cancer develops from the cells present in the inner lining of the stomach that affects the older people in general. The ursolic acid nanoparticles were prepared using the methoxy poly(ethylene glycol)–polycaprolactone (mPEG–PCL) block copolymers as drug carriers by the nano-precipitation method. The produced nanoparticle is nearly spherical, has an average size of 144nm and around 80% encapsulation efficiency. It was found that the free ursolic acid and ursolic acid-loaded nanoparticle had effect on the SGC7901 cells while the nanocarrier alone did produce any toxic effect. Besides, the ursolic acid loaded nanoparticles had a stronger effect and elicited more cell death. The cell death involved the inhibition of COX-2 and activation of caspase-3. Therefore, the study offer an effective way to improve the anticancer efficiency of UA through nano-drug delivery system [100]."
    }, {
      "heading" : "6. Conclusion",
      "text" : "Nature has provided us with a vast verity of things and has become\na part of man’s life. It has not only given us food to eat, water to\ndrink, fresh air to breath but also some other support that would\nsave our life. Phytochemicals are one such beautiful gift that helps\nin curing some threatening diseases. These phytochemicals have\nbeen continuously exploited by the scientists for their medicinal\nproperties such as antibiotic, antioxidant, antifungal, antiviral and\nso on. One of the most prominent property is the anticancer effect\nof the phytochemicals as cancer claims to be the second leading\ncause of death worldwide [10]. A sustained search of a novel\nanticancer drug and a better method of administration has always\nbeen existing. In this scenario the advanced field of nanotechnology\nhas renovated the therapy of cancer to a different level.\nFigure 7: Effect of phytochemicals against cancer cells\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n16 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nThe nano-drug delivery of anticancer agents have interested many in the recent years. This is primarily due their reliable and targeted delivery, increased drug efficiency, improved cellular interaction along with less toxicity to the surroundings. These advantages are same when it comes to a synthetic anticancer drug or a phytochemical with anticancer effect. Fascinatingly, the response elicited by the phytochemicals delivered using nanocarrier is similar to that of the same phytochemical in the free form. However, the half maximal inhibitory concentration of the drug has reduced to a greater extent when nanotechnology is employed (Figure 7). These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50]. The different targets of phytochemicals loaded inside nanocarriers are given in figure 8. Type of cancer Cell line tested Phytochemical Nanocarrier Reference\nA549 human lung adenocarcinomic cells\nHonokiol Poly(ἐ-caprolactone)-poly(ethylene glycol)-\npoly(ἐ-caprolactone) copolymer micelle\n[49]\nNCI-H460 non-small cell lung carcinoma cells\nFerulic acid Poly-d,l-lactide-co-glycolide (PLGA)\nnanoparticles\n[50]\nLung\nA549 human lung adenocarcinomic cells\nβ-Lapachone Poly(ethylene glycol)-co-poly(D,L-lactic\nacid) (PEG-PLA) polymer micelles\n[51]\nA549 human lung adenocarcinomic cells\nβ-Lapachone and Paclitaxel\nPoly(ethylene glycol)-co-poly(D,L-lactic acid) (PEG-PLA) polymer micelles\n[52]\nH292 lung cancer cells Luteolin Ploylactic acid and polyethylene glycol\n(PLA-PEG) nanoparticle\n[53]\nMCF-7 human breast adenocarcinoma cell line and MDA-MB-453\nCurcumin Silk fibroin and chitosan (SFCS) polymers\nnanoparticles\n[54]\nSK-BR-3 human breast cancer cells\nNoscapine Human serum albumin (HSA) nanoparticle [55]\nBreast MDA-MB-231 breast cancer\ncells\nUrsolic acid, pH-sensitive liposomes [56]\nMCF-7 human breast\nadenocarcinoma cell line\nThymoquinone Liposomes modified with Triton X-100 (XLP [57]\nMDA-MB-231 breast cancer cells Silibinin Lipid nanoparticles containing d-αtocopheryl polyethylene glycol 1000\nsuccinate (TPGS) and phosphatidylcholine\n[58]\nMCF-7 human breast\nadenocarcinoma cell line\nGallic acid PAMAM dendrimers [59]\nHT29 human adenocarcinoma cells\nTriptolide MePEG-PLA copolymer micelle [60]\nCT26 murine colon carcinoma cells\nHonokiol Monomethoxy poly (ethylene glycol)\n(MPEG) and poly (ἐ-caprolactone) (PCL) star shaped micelle\n[61]\nColorectal HCT 116 human colon\ncancer cells\nThymoquinone Poly (lactide-co-glycolide) (PLGA)\nnanoparticles\n[62]\nC-26 colon carcinoma cells Luteolin, Monomethoxy poly(ethylene glycol)- [63]\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 17\npoly(ε-caprolactone) (MPEG-PCL) micelles\nCT-26 colon cancer cells Curcumin Curcumin nanoparticles anchored with\nC18PMH-PEG on the surface\n[64]\nA375 skin melanoma and HaCaT keratinocytes\nApigenin Poly (lactic-co-glycolide) nanoparticles [65, 66]\nMelanoma B16 and B16F10 melanoma\ncells\nCombretastatin A-4 and Doxorubisin\nRGD (Arginylglycylaspartic acid)-modified liposomes\n[67]\nMel 928 melanoma cells Epigallocatechin 3-\ngallate (EGCG)\npolylactic acid-polyethylene glycol nanoparticles\n[68]\nA2780 human ovarian cancer cells\nHonokiol Monomethoxy poly(ethylene glycol)–\npoly(lactic acid) (MPEG–PLA) nanocarrier\n[69]\nOvarian A2780CP ovarian cancer\ncells\nCurcumin Poly(lactic-co-glycolide) (PLGA)\nnanoparticle\n[70]\nSKOV ovarian cancer cells Resveratrol Bovine serum albumin nanoparticles [71]\nSKOV-3 ovarian cancer cells Curcumin Poly(2-hydroxyethyl methacrylate)\n[PHEMA] nanoparticles\n[72]\nLNCaP human prostate adenocarcinoma cells and PCa prostate cancer cells\nPolylactic acid-polyethylene glycol prostate-specific membrane antigen (PSMA) ligands\n[73]\nPC-3 human prostate cancer cells\nEpigallocatechin 3- gallate (EGCG)\nBovine serum albumin nanoparticles [74]\nProstate PCa prostate cancer cells Polylactic acid–polyethylene glycol (PLA-\nPEG) nanocarrier\n[75]\nLNCaP human prostate adenocarcinoma cells, PC3 human prostate cancer cells and DU-145 PC3 human prostate cancer cells\nCurcumin Poly (lactic-coglycolic acid) (PLGA)\nnanospheres\n[76]\nPTEN-CaP8 Mouse prostate epithelium cancer cells Curcumin and resveratrol\nCurcumin and resveratrol nanoemulsions [77]\nBovine casein micelles [78]\nCervical HeLa cervical cancer cells Curcumin Alginate-chitosan-pluronic composite\nnanoparticles\n[79]\nBerberine Berberine polyethenyl glycol (PEG)\nliposome\n[80]\nHepG2 hepatocellular carcinoma cells\nBerberine Berberine and D-α-tocopheryl\npolyethylene glycol 1000 succinate (TPGS) nanosuspension\n[81]\nGambogic acid Lactoferrine nanoparticles [82]\nHepatoma Apigenin Pluronic P123 and Solutol HS 15 polymeric [83]\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H\nREVIEW RSC Advances\n18 | RSC Adv., 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015\nmicelle\nCurcumin Gum Arabic nanoparticles [84]\nResveratrol Resveratrol and poloxamer 188\nnanosuspension\n[85]\nCurcumin N-isopropylacrylamide (NIPAAM), with N-\nvinyl-2-pyrrolidone (VP) and poly(ethyleneglycol)monoacrylate (PEG-A).\n[86]\nCholesteryl-hyaluronic acid (CHA) nanogel [87]\nPancreatic MiaPaca pancreatic cancer\ncell line\nDifluorobenzylidene curcumin (CDF)\nStyrene-maleic acid copolymer (SMA) micelle\n[88]\nPoly(amidoamine) (PAMAM) and hyaluronic acid nanocarrier\n[89]\nOral KB human oral cancer cells Dihydroartemisinin Methoxy poly(ethylene glycol)/poly(L-lactic\nacid) (mPEG) micelles\n[90]\nEllagic acid Chitosan nanoparticle [91]\nKBM-5 myeloid leukemia cells\nCurcumin Poly (lactide-co-glycolide) (PLGA) and\npolyethylene glycol (PEG) nanoparticles\n[92]\nK562 myeloid leukemia cells\nDoxorubicin and Curcumin\nPoly- (D,L-lactide-co-glycolide) nanoparticles\n[93]\nLeukemia L1210 mouse lymphocytic\nleukemia cells and K562 myeloid leukemia cells\nEmodin D-α-tocopheryl polyethylene glycol 1000\nsuccinate (TPGS) liposomes\n[94]\nRAW264.7 Abelson murine leukemia virus-induced tumor cell lines Nobiletin Chitosan nanoparticles [95]\nJurkat acute lymphoblastic leukemia cells\nZerumbone Nanostructured lipid carriers [96]\nGlioma C6 glioma cells Resveratrol mPEG-PCL nanoparticles [97]\nNeuroblastoma SH-SY5Y neuroblastoma Curcumin Apolipoprotein E3 mediated poly(butyl)\ncyanoacrylate nanoparticles\n[98]\nMyeloma Myeloma cells Curcumin Poly(oxyethylene) cholesteryl ether (PEG-\nChol micelles\n[99]\nGastric SGC7901 gastric cancer\ncells\nUrsolic acid Methoxy poly(ethylene glycol)–\npolycaprolactone (mPEG–PCL) nanocarrier\n[100]\nTable 2: Summary of phytochemicals and their nanocarrier employed against various cancers\nThe review summarized the nano-drug delivery of more than fifteen phytochemicals against various types of cancer. Among them, the yellow diarylheptanoid compound curcumin has been exploited almost against all types of cancer enlisted in the review. The phytochemicals like apigenin, resveratrol, honokiol and epigallocatechin gallate (EGCG) are other commonly tested compounds. Anyhow the phytochemicals are found to become\nmore hydrophilic in nature when attached to the nanocarrier. From our studies it is found that the most regularly preferred nanocarrier is a micelle with a polymeric base. A micelle is a nanostructure which has both hydrophobic part and a hydrophilic part. The common polymeric bases employed for the micelle are poly(ethylene glycol) (PEG), poly lactic-acid (PLA), poly-lactide-coglycolide (PLGA), and methoxy poly(ethylene glycol) (mPEG) which are known for their good biocompatible and biodegradable\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6R 07802H"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 19\nbehaviour. Apart from the nano-micelles the dendrimers, liposomes, nanocomposites and nanoparticles act as the nanocarriers for delivering drug.\nFigure 8: Molecular targets of phytochemicals loaded inside nanocarriers against cancer cell\nThe nano-drug delivery of phytochemicals have been extensively investigated by a large number of cell studies and a few animal studies. The preclinical testing with the normal mouse, nude mice and knock out mouse bearing cancer cells have showed a suppression in the tumor growth. Besides these positive aspects, there is a lack of studies that deals with the toxicity and other adverse effect that are produced by the nanocarriers. Hence, more in depth studies relating to the genotoxicity of the nanocarriers and its other possible side effects should be initiated. More over the phytochemicals are known to exhibit synergistic effect against the cancer cells. It is their ability to increase a particular property when used in combination. Previous studies have shown phytochemicals when combined have improved cytotoxicity towards cancer cells [101]. It would be interesting to investigating the outcome of these combination with nano-drug delivery for cancer. In addition to this, clinical studies on nano-drug delivery as well as the mode of administration should be carried out to promote them in the field of medicinal oncology."
    }, {
      "heading" : "Acknowledgments",
      "text" : "This work was supported partly by the Research University Grant\nscheme with the Grant Vot No: Q.J130000.2509.10H13 and also\nacknowledges the support of UPMU, UTM.\nNotes and references a\nIJN-UTM Cardiovascular Engineering Centre, Faculty of Biosciences and Medical Engineering, Universiti Teknologi Malaysia, Johor Bahru 81310, Malaysia b Department of Chemistry, Bharath University, Chennai 600073, Tamil\nNadu, India c Surface Engineering Laboratory, Department of Physics, Sri Shakthi\nInstitute of Engineering and Technology, L&T by pass, Chinniyam\nPalayam, Coimbatore-641062, India d Department of Chemistry, Indian Institute of Space Science and\nTechnology, Thiruvananthapuram, Kerala 695547, India.\n* Corresponding author\nDr Saravana Kumar Jaganathan, IJN-UTM Cardiovascular Engineering\nCentre, Faculty of Biosciences and Medical Engineering, University\nTeknologi Malaysia, Johor Bahru 81310, Malaysia :Email:\njaganathaniitkgp@gmail.com:Tel : 00607-5558548:Fax: 07-5558553"
    }, {
      "heading" : "RSC Advances REVIEW",
      "text" : "This journal is © The Royal Society of Chemistry 2015 RSC Adv., 2015,00, 5-11| 21\n67. Y. Zhang, J. Wang, D. Bian, X. Zhang, Q. Zhang. European\nJournal of Pharmaceutics and Biopharmaceutics. 2010, 74\n(2010), 467–473.\n68. I.A. Siddiqui, D.J. Bharali, M. Nihal, V. M. Adhami, N. Khan,\nJ.C. Chamcheu, M. I. Khan, S.Shabana, S.A. Mousa, H.\nMukhtar. Nanomedicine: Nanotechnology, Biology, and\nMedicine 2014, 10 (2014) 1619–1626\n69. X. L Zheng, B. Kan, M.L. Gou, S.Z. Fu, J. Zhang, K. Men, L.J\nChen, F. Luo, Y.L. Zhao, X. Zhao, Y.Q Wei, Z.Y Qian.\nInternational Journal of Pharmaceutics. 2010, 386 (2010),\n262–267.\n70. M. M. Yallapu, B.K. Gupta, M. Jaggi, S.C. Chauhan. Journal of\nColloid and Interface Science, 2010, 351 (2010), 19–29.\n71. L. Guo, Y. Peng, J. Yao, L. Sui, A. Gu, J. Wang. Cancer Biother\nRadiopharm. 2010, 25(4), 471-7.\n72. S.S.D Kumar, S. Mahadevan, R. Vijayaraghavan, A.B Mandal,\nD.R. MacFarlane. European Journal of Pharmaceutical\nSciences. 2014, 51 (2014), 34–44.\n73. V. Sanna, G. Pintus, A.M. Roggio, S. Punzoni, A. M. Posadino,\nA. Arca, S. Marceddu, P. Bandiera, S. Uzzau, and M. Sechi. J.\nMed. Chem. 2011, 54, 1321–1332\n74. Y.G Zu, S.Yuan, X.H Zhao, Y. Zhang, X.N Zhang, R. Jiang, X.X.\nBao. 2009, 44(5), 525-31.\n75. I.A. Siddiqui, V.M. Adhami, D. J. Bharali, B. B. Hafeez, M.\nAsim, S.I. Khwaja, N. Ahmad, H. Cui, S. A. Mousa, and H.\nMukhtar. Cancer Res. 2009, 69(5), 1712–1716.\n76. A. Mukerjee and J.K. Vishwanatha. Anticancer research.\n2009, 29, 3867-3876.\n77. N.K. Narayanan, D. Nargi, C. Randolph and B. A. Narayanan.\nInt. J. Cancer, 2009, 125, 1–8.\n78. A. Sahu, N. Kasoju, and U. Bora. Biomacromolecules 2008, 9,\n2905–2912.\n79. R.K. Das, N. Kasoju, U. Bora. Nanomedicine:\nNanotechnology, Biology, and Medicine 2010, 6 (2010),\n153–160.\n80. Y.C Lin, J.Y. Kuo, C.C Hsu, W.C Tsai, W.C Li, M.C Yu, H. W\nWen. International Journal of Pharmaceutics. 2013, 441\n(2013), 381– 388.\n81. Z. Wang, J. Wu, Q. Zhou, Y. Wang, T. Chen. Anti-\nhepatocarcinoma effects of berberine nanosuspension\nagainst human HepG2 and Huh7 cells as well as H22 tumor\nbearing mice. Twelfth International Conference on\nPhotonics and Imaging in Biology and Medicine (PIBM 2014)\n82. Z.H Zhang, X.P Wang, W.Y Ayman, W.L Munyendo, H.X Lv,\nJ.P Zhou. Drug Deliv. 2013, 20(2), 86-93.\n83. Y. Zhaia, S. Guo, C. Liu, C. Yang, J. Dou, L. Li, G. Zhai. Colloids\nand Surfaces A: Physicochem. Eng. Aspects 2013, 429\n(2013), 24– 30.\n84. P.R. Sarikaa, N.R Jamesa, P.R. Anil Kumar, D.K. Raj, T.V.\nKumary. Carbohydrate Polymers. 2015, 134 (2015), 167–\n174.\n85. S.Q. Luo, W.L Lu, Y. F Wang and Z.P. Wang. Advance Journal\nof Food Science and Technology. 2015, 8(3), 210-213.\n86. S. Bisht, G. Feldmann, S. Soni, R. Ravi, C. Karikar. Journal of\nNanobiotechnology. 2007, 5:3: 1-18.\n87. X. Wei, T.H. Senanayake, A. Bohling, and S.V. Vinogradov.\nMol. Pharmaceutics 2014, 11, 3112−3122.\n88. P. Kesharwani, S. Banerjee, S. Padhye, F.H. Sarkar, A.K. Iyer.\nColloids and Surfaces B: Biointerfaces 2015, 132 (2015),\n138–145.\n89. P. Kesharwani, L. Xie, S. Banerjee, G. Mao, S. Padhye, F. H.\nSarkarc, A.K. Iyer. Colloids and Surfaces B: Biointerfaces\n2015, 136 (2015), 413–423.\n90. W. Lu, S. Chen, Z. Wen, Q. Li, J. Chen. J. Appl. Polym. Sci.\n2013. 3084-3093.\n91. V. Arulmozhia, K. Pandianb, S. Mirunalinia. Colloids and\nSurfaces B: Biointerfaces 2013, 110 (2013), 313– 320.\n92. P. Anand, H.B. Nair, B. Sung, A. B. Kunnumakkara, V.R.\nYadav, R.R. Tekmal and B. B. Aggarwal. Biochem Pharmacol.\n2010, 79(3), 330–338.\n93. R. Misra and S.K. Sahoo. Mol. Pharmaceutics. 2011, 8, 852–\n866.\n94. T. Wang, X. Yin, Y. Lu, W. Shan, S. Xiong. International\nJournal of Nanomedicine. 2012, 7, 2325–2337.\n95. A.G. Luque-Alcaraz, J. Lizardi, F.M. Goycoole, M.A. Valdez, A.\nL. Acosta, S.B. Iloki-Assanga, I. Higuera-Ciapara and W.\nArg¨uelles-Monal. Journal of Nanomaterials. 2012, 2012, 1-\n7.\n96. H. S. Rahman, A. Rasedee, C.W How, A.B. Abdul, N.A\nZeenathu, H.H. Othman, M. I. Saeed, S. K. Yeap.\nInternational Journal of Nanomedicine. 2013, 8, 2769–2781.\n97. J. Shao, X. Li, X. Lu, C. Jiang, Y. Hu, Q. Li, Y. You, Z.Fu. Colloids\nand Surfaces B: Biointerfaces. 2009, 72 (2009) 40–47.\n98. R.S. Mulik, J. Mo¨nkko¨nen, R.O. Juvonen, K.R. Mahadik, and\nA. R. Paradkar. Molecular Pharmaceutics. 7( 3), 815–825.\n99. K. Sou, B. Oyajobi, B. Goins, W.T Phillips, E. Tsuchida. J\nBiomed Nanotechnol. 2009, 5(2), 202-208.\n100. H. Zhang, X. Li, J. Ding, H. Xu, X. Dai, Z. Hou, K. Zhang, K. Sun,\nW. Sun. International Journal of Pharmaceutics. 2013, 441\n(2013), 261– 268.\n101. R.H Liu. J Nutr. 2004 Dec;134(12 Suppl):3479S-3485S.\nR S\nC A\ndv an\nce s\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n0 4\nM ay\n2 01\n6. D\now nl\noa de\nd by\nU ni\nve rs\nity o\nf Su\nss ex\no n\n06 /0\n5/ 20\n16 0\n8: 15\n:3 0.\nView Article Online DOI: 10.1039/C6RA07802H"
    } ],
    "references" : [ {
      "title" : "Time Tables of Medicine",
      "author" : [ "G. Davies" ],
      "venue" : "Black Dog & Leventhal; New York:",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "Anti",
      "author" : [ "H. Wang", "T.O Khor", "L. Shu", "Z. Su", "F. Fuentes", "J.H. Lee", "A.T Kong" ],
      "venue" : "Agents Med Chem.",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Pharm",
      "author" : [ "I.A. Siddiqui", "H. Mukhtar" ],
      "venue" : "Res.",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Nat",
      "author" : [ "N. Nishiyama" ],
      "venue" : "Nanotechnol.",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Modern Concepts in Nanotechnology, Discovery",
      "author" : [ "S.K. Prasad" ],
      "venue" : "Publishing House,",
      "citeRegEx" : "8",
      "shortCiteRegEx" : "8",
      "year" : 2008
    }, {
      "title" : "Nat",
      "author" : [ "M. Ferrari" ],
      "venue" : "Rev. Cancer.",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "M",
      "author" : [ "A.G Cuenca", "H. Jiang", "S.N Hochwald" ],
      "venue" : "Delano, W.G Cance, S.R Grobmyer. Cancer",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Cancer Biology & Therapy",
      "author" : [ "V Malhotra", "MC Perry" ],
      "venue" : null,
      "citeRegEx" : "13",
      "shortCiteRegEx" : "13",
      "year" : 2003
    }, {
      "title" : "Cancer Chemotherapy and Biotherapy: Principles and Practice (4th ed.)",
      "author" : [ "B Chabner", "DL Longo" ],
      "venue" : null,
      "citeRegEx" : "14",
      "shortCiteRegEx" : "14",
      "year" : 2005
    }, {
      "title" : "Cell and Tissue",
      "author" : [ "Makin G", "Hickman JA" ],
      "venue" : "Research 2000",
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2000
    }, {
      "title" : "Plant Physiology (4th edition), Wadsworth Publishing, Belmont, California",
      "author" : [ "F.B Salisbury", "W.R Cleon" ],
      "venue" : "1991, 325–326.  Page 19 of 21  RSC Advances R  S  C  A  dv  an  ce  s  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  4  M  ay  2  01 6.  D  ow  nl  oa  de  d  by  U  ni  ve  rs  ity  o  f  Su  ss  ex  o  n  06  /0  5/  20  16  0  8:  15  :3 0.  View Article Online DOI: 10.1039/C6RA07802H  REVIEW RSC Advances 20 | RSC Adv.,",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Phytochemicals in Nutrition and Health",
      "author" : [ "M.S Meskin", "W.R Bidlack", "A.J Davies", "S.T Omaye" ],
      "venue" : null,
      "citeRegEx" : "22",
      "shortCiteRegEx" : "22",
      "year" : 2002
    }, {
      "title" : "E",
      "author" : [ "S.K Jaganathan" ],
      "venue" : "Supriyanto. Molecules.",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Eerdunbayaer, A",
      "author" : [ "M.B Li" ],
      "venue" : "Nozaki, E. Takahashi, K. Okamoto, H. Ito, T. Hatano. Heterocycles",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "chapter 2 : Chemistry and classification of phytochemicals",
      "author" : [ "V. Rocio Campos", "B.D Oomah" ],
      "venue" : "Handbook of Plant Food Phytochemicals.",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Optimal nutrition: fibre and phytochemicals",
      "author" : [ "I. Rowland" ],
      "venue" : "Proceedings of the Nutrition Society,",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "The Journal of Nutrition",
      "author" : [ "R.P Heaney" ],
      "venue" : null,
      "citeRegEx" : "31",
      "shortCiteRegEx" : "31",
      "year" : 2001
    }, {
      "title" : "L",
      "author" : [ "C. Manach", "A. Scalbert", "C.H Morand", "C.H Rémesy" ],
      "venue" : "Jimenez. American Journal of Clinical Nutrition.",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "G",
      "author" : [ "K. Németh", "G.W. Plumb", "J.G Berrin", "N. Juge", "R. Jacob", "H.Y Naim" ],
      "venue" : "Williamson, D.M. Swallow, P.A Kroon. Eur J Nutr.",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "A",
      "author" : [ "C. Manach", "G. Williamsom", "C.H Morand" ],
      "venue" : "Scalbert, C.H Rémesy. American Journal of Clinical Nutrition.",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "I",
      "author" : [ "T.D. Tailor", "G. Hanna", "P.S Yarmolenko", "M.R Dreher", "A.S Betof", "A.B Nixon" ],
      "venue" : "Spasojevic, M.W Dewhirst. Mol Cancer Ther.",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "D",
      "author" : [ "A.A Manzoor", "L.H Lindner", "C.D. Landon", "J.Y Park", "A.J Simnick", "M.R Dreher", "S. Das", "G. Hanna", "W. Park", "A. Chilkoti", "G.A Koning", "T.L.M. Hagen" ],
      "venue" : "Needham, M.W Dewhirst. Cancer Res.",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "R",
      "author" : [ "D. Peer", "J. Kar", "S. Hong", "O. Farokhzad" ],
      "venue" : "Langer. Nature.",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Nanotechnology: The Future Medicine",
      "author" : [ "Rajiv Saini", "Santosh Saini", "Sugandha Sharma" ],
      "venue" : "Journal of Cutaneous and Aesthetic Surgery",
      "citeRegEx" : "38",
      "shortCiteRegEx" : "38",
      "year" : 2010
    }, {
      "title" : "Cancer nanotechnology: opportunities and challenges",
      "author" : [ "Mauro Ferrari" ],
      "venue" : "Nature Reviews Cancer",
      "citeRegEx" : "39",
      "shortCiteRegEx" : "39",
      "year" : 2005
    }, {
      "title" : "R",
      "author" : [ "R. Nagarajan" ],
      "venue" : "Langmuir",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "J",
      "author" : [ "H.-C. Wu", "D.-K. Chang", "C.-T. Huang" ],
      "venue" : "Cancer Mol,",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "A",
      "author" : [ "E. Pérez-Herrero" ],
      "venue" : "Fernández-Medarde. European Journal of Pharmaceutics and Biopharmaceutics.",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "M",
      "author" : [ "J.P. Jose Merlina", "N. Rajendra Prasada", "S.M.A. Shibli" ],
      "venue" : "Sebeel. Biomedicine & Preventive Nutrition.",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Mol",
      "author" : [ "L. Zhang", "Z. Chen", "K. Yang", "C. Liu", "J. Gao", "F. Qian" ],
      "venue" : "Pharmaceutics",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Amin1, Z",
      "author" : [ "D. Majumdar", "K.H Jung", "H.Z. Zhang", "S. Nannapaneni", "X. Wang", "A.R.M Ruhu" ],
      "venue" : "Chen, G. Zhuo. and M. D. Shin. Cancer Prev Res (Phila).",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "B",
      "author" : [ "V. Gupta", "A. Aseh", "C.N Ríos" ],
      "venue" : "B Aggarwal, A.B. Mathur. International Journal of Nanomedicine",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "A",
      "author" : [ "F. Odeh", "S.I. Ismail", "R. Abu-Dahab", "I.S Mahmoud" ],
      "venue" : "Bawab. Drug Deliv.",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Y",
      "author" : [ "P. Xu", "Q. Yin", "J. Shen", "L. Chen", "H. Yu", "Z. Zhang" ],
      "venue" : "Li. International Journal of Pharmaceutics",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Surface modified dendrimers",
      "author" : [ "A. Sharma", "S.P. Gautam", "A.K Gupta" ],
      "venue" : "Bioorganic & Medicinal Chemistry. 2011,",
      "citeRegEx" : "59",
      "shortCiteRegEx" : "59",
      "year" : 2011
    }, {
      "title" : "H",
      "author" : [ "S. Zheng", "K. Löw", "S. Wagner", "X. Yang" ],
      "venue" : "von Briesen, S. Zou. Toxicology in vitro",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Colloids and Surfaces A: Physicochem",
      "author" : [ "P.W Dong", "X.H Wang", "Y.C. Gu", "Y.J. Wang", "Y.J. Wang", "C.Y. Gong", "F. Luo", "G. Guo", "X. Zhao", "Y.Q. Wei", "Z.Y. Qian" ],
      "venue" : "Eng. Aspects",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "R",
      "author" : [ "J. Ravindran", "H.B. Nair", "B. Sung", "S. Prasad" ],
      "venue" : "R. Tekmal, B.B. Aggarwal. Biochemical Pharmacology",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "X",
      "author" : [ "J. Zhang", "S. Li", "F.F An", "J. Liu", "S. Jin", "J.C. Zhang", "P.C. Wang" ],
      "venue" : "Zhang, C.S. Lee and X.J Liang. Nanoscale,",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Food and Chemical Toxicology",
      "author" : [ "S. Das", "J. Das", "A. Samadder", "A. Paul", "A.R. Khuda-Bukhs" ],
      "venue" : "2013, 62 (2013), 670–680.  Page 20 of 21  RSC Advances R  S  C  A  dv  an  ce  s  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  4  M  ay  2  01 6.  D  ow  nl  oa  de  d  by  U  ni  ve  rs  ity  o  f  Su  ss  ex  o  n  06  /0  5/  20  16  0  8:  15  :3 0.  View Article Online DOI: 10.1039/C6R 07802H  RSC Advances  REVIEW This journal is © The Royal Society of Chemistry",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Q",
      "author" : [ "Y. Zhang", "J. Wang", "D. Bian", "X. Zhang" ],
      "venue" : "Zhang. European Journal of Pharmaceutics and Biopharmaceutics.",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "M",
      "author" : [ "I.A. Siddiqui", "D.J. Bharali", "M. Nihal", "V.M. Adhami", "N. Khan", "J.C. Chamcheu" ],
      "venue" : "I. Khan, S.Shabana, S.A. Mousa, H. Mukhtar. Nanomedicine: Nanotechnology, Biology, and Medicine",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "X",
      "author" : [ "X. L Zheng", "B. Kan", "M.L. Gou", "S.Z. Fu", "J. Zhang", "K. Men", "L.J Chen", "F. Luo", "Y.L. Zhao" ],
      "venue" : "Zhao, Y.Q Wei, Z.Y Qian. International Journal of Pharmaceutics.",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "M",
      "author" : [ "M.M. Yallapu", "B.K. Gupta" ],
      "venue" : "Jaggi, S.C. Chauhan. Journal of Colloid and Interface Science,",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "J",
      "author" : [ "L. Guo", "Y. Peng", "J. Yao", "L. Sui", "A. Gu" ],
      "venue" : "Wang. Cancer Biother Radiopharm.",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "R",
      "author" : [ "S.S.D Kumar", "S. Mahadevan" ],
      "venue" : "Vijayaraghavan, A.B Mandal, D.R. MacFarlane. European Journal of Pharmaceutical Sciences.",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "J",
      "author" : [ "V. Sanna", "G. Pintus", "A.M. Roggio", "S. Punzoni", "A.M. Posadino", "A. Arca", "S. Marceddu", "P. Bandiera", "S. Uzzau", "M. Sechi" ],
      "venue" : "Med. Chem.",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "and H",
      "author" : [ "I.A. Siddiqui", "V.M. Adhami", "D.J. Bharali", "B.B. Hafeez", "M. Asim", "S.I. Khwaja", "N. Ahmad", "H. Cui", "S.A. Mousa" ],
      "venue" : "Mukhtar. Cancer Res.",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Anticancer research",
      "author" : [ "A. Mukerjee", "J.K. Vishwanatha" ],
      "venue" : null,
      "citeRegEx" : "76",
      "shortCiteRegEx" : "76",
      "year" : 2009
    }, {
      "title" : "Int",
      "author" : [ "N.K. Narayanan", "D. Nargi", "C. Randolph", "B.A. Narayanan" ],
      "venue" : "J. Cancer,",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "and U",
      "author" : [ "A. Sahu", "N. Kasoju" ],
      "venue" : "Bora. Biomacromolecules",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "U",
      "author" : [ "R.K. Das", "N. Kasoju" ],
      "venue" : "Bora. Nanomedicine: Nanotechnology, Biology, and Medicine",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "H",
      "author" : [ "Y.C Lin", "J.Y. Kuo", "C.C Hsu", "W.C Tsai", "W.C Li", "M.C Yu" ],
      "venue" : "W Wen. International Journal of Pharmaceutics.",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Antihepatocarcinoma effects of berberine nanosuspension against human HepG2 and Huh7 cells as well as H22 tumor bearing mice",
      "author" : [ "Z. Wang", "J. Wu", "Q. Zhou", "Y. Wang", "T. Chen" ],
      "venue" : "Twelfth International Conference on Photonics and Imaging in Biology and Medicine (PIBM",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Colloids and Surfaces A: Physicochem",
      "author" : [ "Y. Zhaia", "S. Guo", "C. Liu", "C. Yang", "J. Dou", "L. Li", "G. Zhai" ],
      "venue" : "Eng. Aspects",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Y",
      "author" : [ "S.Q. Luo", "W.L Lu" ],
      "venue" : "F Wang and Z.P. Wang. Advance Journal of Food Science and Technology.",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "C",
      "author" : [ "S. Bisht", "G. Feldmann", "S. Soni", "R. Ravi" ],
      "venue" : "Karikar. Journal of Nanobiotechnology.",
      "citeRegEx" : "86",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Mol",
      "author" : [ "X. Wei", "T.H. Senanayake", "A. Bohling", "S.V. Vinogradov" ],
      "venue" : "Pharmaceutics",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "S",
      "author" : [ "P. Kesharwani", "S. Banerjee" ],
      "venue" : "Padhye, F.H. Sarkar, A.K. Iyer. Colloids and Surfaces B: Biointerfaces",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "F",
      "author" : [ "P. Kesharwani", "L. Xie", "S. Banerjee", "G. Mao", "S. Padhye" ],
      "venue" : "H. Sarkarc, A.K. Iyer. Colloids and Surfaces B: Biointerfaces",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "J",
      "author" : [ "W. Lu", "S. Chen", "Z. Wen", "Q. Li", "J. Chen" ],
      "venue" : "Appl. Polym. Sci.",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "S",
      "author" : [ "V. Arulmozhia", "K. Pandianb" ],
      "venue" : "Mirunalinia. Colloids and Surfaces B: Biointerfaces",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "and B",
      "author" : [ "P. Anand", "H.B. Nair", "B. Sung", "A.B. Kunnumakkara", "V.R. Yadav", "R.R. Tekma" ],
      "venue" : "B. Aggarwal. Biochem Pharmacol.",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Mol",
      "author" : [ "R. Misra", "S.K. Sahoo" ],
      "venue" : "Pharmaceutics.",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "S",
      "author" : [ "T. Wang", "X. Yin", "Y. Lu", "W. Shan" ],
      "venue" : "Xiong. International Journal of Nanomedicine.",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "̈uelles-Monal",
      "author" : [ "A.G. Luque-Alcaraz", "J. Lizardi", "F.M. Goycoole", "M.A. Valdez", "A.L. Acosta", "S.B. Iloki-Assanga", "I. Higuera-Ciapara", "W. Ar" ],
      "venue" : "Journal of Nanomaterials. 2012,",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "S",
      "author" : [ "H.S. Rahman", "A. Rasedee", "C.W How", "A.B. Abdul", "N.A Zeenathu", "H.H. Othman", "M.I. Saeed" ],
      "venue" : "K. Yeap. International Journal of Nanomedicine.",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Y",
      "author" : [ "J. Shao", "X. Li", "X. Lu", "C. Jiang", "Y. Hu", "Q. Li" ],
      "venue" : "You, Z.Fu. Colloids and Surfaces B: Biointerfaces.",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "E",
      "author" : [ "K. Sou", "B. Oyajobi", "B. Goins", "W.T Phillips" ],
      "venue" : "Tsuchida. J Biomed Nanotechnol.",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "W",
      "author" : [ "H. Zhang", "X. Li", "J. Ding", "H. Xu", "X. Dai", "Z. Hou", "K. Zhang", "K. Sun" ],
      "venue" : "Sun. International Journal of Pharmaceutics.",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "A  dv  an  ce  s  A  cc  ep  te  d  M  an  us  cr  ip t Pu  bl  is  he  d  on  0  4  M  ay  2  01 6.  D  ow  nl  oa  de  d  by  U  ni  ve  rs  ity  o  f  Su  ss  ex  o  n",
      "author" : [ "R.H Liu" ],
      "venue" : "J Nutr",
      "citeRegEx" : "101",
      "shortCiteRegEx" : "101",
      "year" : 2004
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "Consumption of naturally available plant derived products have been used to prevent as well as treat various diseases for many centauries by the man kind [1].",
      "startOffset" : 154,
      "endOffset" : 157
    }, {
      "referenceID" : 1,
      "context" : "Apart from this, there are many literature proofs to show the various health benefits of phytochemicals present in them [3, 4,5].",
      "startOffset" : 120,
      "endOffset" : 128
    }, {
      "referenceID" : 2,
      "context" : "Apart from this, there are many literature proofs to show the various health benefits of phytochemicals present in them [3, 4,5].",
      "startOffset" : 120,
      "endOffset" : 128
    }, {
      "referenceID" : 3,
      "context" : "The nano-based formulations are found to improve solubility, bioavailability, specific targeting while reducing the doses and achieving steady-state therapeutic levels in cancer treatment [7].",
      "startOffset" : 188,
      "endOffset" : 191
    }, {
      "referenceID" : 4,
      "context" : "In general, all the biological process that happens inside the body, including the origin and prognosis of cancer, are said to occur in the nano-level [8].",
      "startOffset" : 151,
      "endOffset" : 154
    }, {
      "referenceID" : 5,
      "context" : "According to the survey, about 595,690 Americans are expected to die of cancer and 1,685,210 new cancer cases diagnosed in US during the year 2016 [10].",
      "startOffset" : 147,
      "endOffset" : 151
    }, {
      "referenceID" : 6,
      "context" : "One such more advanced mode of treatment type is the cancernanotechnology, which combines nanomedicine and cancer [11].",
      "startOffset" : 114,
      "endOffset" : 118
    }, {
      "referenceID" : 7,
      "context" : "It mainly utilizes one or more chemical substance known as anticancer drug or chemotherapeutic drug [13].",
      "startOffset" : 100,
      "endOffset" : 104
    }, {
      "referenceID" : 8,
      "context" : "This treatment is adopted before, after or during other types of treatment procedures such as radiotherapy, surgery and targeted radiotherapy [14].",
      "startOffset" : 142,
      "endOffset" : 146
    }, {
      "referenceID" : 9,
      "context" : "Apoptosis is a programmed cell death in multicellular organisms involving a series of biochemical changes as well as morphological change finally leading to the death of the cell [17].",
      "startOffset" : 179,
      "endOffset" : 183
    }, {
      "referenceID" : 10,
      "context" : "These compounds are produced by plants as a protection against the different environmental stresses which includes insects, bacteria, funguses and weather changes [21].",
      "startOffset" : 163,
      "endOffset" : 167
    }, {
      "referenceID" : 11,
      "context" : "A plant contains a variety of phytochemicals and a same phytochemical is present in more than one plant [22].",
      "startOffset" : 104,
      "endOffset" : 108
    }, {
      "referenceID" : 13,
      "context" : "Whereas clove contains acetyl eugenol, beta-caryophyllene, vanillin, crategolic acid, bicornin, gallotannic acid, methyl salicylate, eugenin, kaempferol, rhamnetin, eugenitin, oleanolic acid, stigmasterol, campesterol, and several sesquiterpenes [24].",
      "startOffset" : 246,
      "endOffset" : 250
    }, {
      "referenceID" : 14,
      "context" : "In order to maintain a class these plant derived compounds have been classified into groups and subgroups based on their functional groups, structures and biosynthetic origins [25].",
      "startOffset" : 176,
      "endOffset" : 180
    }, {
      "referenceID" : 15,
      "context" : "The phytochemicals when consumed along with the diet have been proven effective in fighting many chronic diseases especially, the cardiovascular disorders and cancer [26].",
      "startOffset" : 166,
      "endOffset" : 170
    }, {
      "referenceID" : 16,
      "context" : "In case of other dietary supplements or medicinal herbs the bioavailability is very deprived when they are consumed orally [31].",
      "startOffset" : 123,
      "endOffset" : 127
    }, {
      "referenceID" : 17,
      "context" : ", found that the bioavailability of dietary polyphenols is influenced by the absorption in the gut, microbiota metabolism, glucuronide excretion to the intestinal lumen, plasma kinetics, liver and gut metabolism, accumulation in tissues and bile, urinary excretion and a variety of metabolites in the bloodstream, bonding to albumin, cell assimilation and metabolism [32].",
      "startOffset" : 367,
      "endOffset" : 371
    }, {
      "referenceID" : 18,
      "context" : "The anthocyanins are quite rapidly absorbed, but their bioavailability seems to be the lowest of all flavonoids [33].",
      "startOffset" : 112,
      "endOffset" : 116
    }, {
      "referenceID" : 19,
      "context" : "The bioavailability of the phytochemicals is also influenced by the esterification process [34]",
      "startOffset" : 91,
      "endOffset" : 95
    }, {
      "referenceID" : 20,
      "context" : "The maximum penetration of free doxorubicin was limited to 34μm previously while this study depicted about 78μm diffusion distance in the both sides of the capillary bed in the tumor [35, 36].",
      "startOffset" : 183,
      "endOffset" : 191
    }, {
      "referenceID" : 21,
      "context" : "The maximum penetration of free doxorubicin was limited to 34μm previously while this study depicted about 78μm diffusion distance in the both sides of the capillary bed in the tumor [35, 36].",
      "startOffset" : 183,
      "endOffset" : 191
    }, {
      "referenceID" : 14,
      "context" : "The maximum penetration of doxorubicin was limited to 34μm previously while this study depicted about 78μm diffusion distance in the both sides of the capillary bed in the tumor [25, 26].",
      "startOffset" : 178,
      "endOffset" : 186
    }, {
      "referenceID" : 15,
      "context" : "The maximum penetration of doxorubicin was limited to 34μm previously while this study depicted about 78μm diffusion distance in the both sides of the capillary bed in the tumor [25, 26].",
      "startOffset" : 178,
      "endOffset" : 186
    }, {
      "referenceID" : 22,
      "context" : "In almost all cases these application involve the usage of nanomaterials [37].",
      "startOffset" : 73,
      "endOffset" : 77
    }, {
      "referenceID" : 23,
      "context" : "This noanosystem may also be called nanocarrier [38].",
      "startOffset" : 48,
      "endOffset" : 52
    }, {
      "referenceID" : 24,
      "context" : "This is due to the fact that these nanocarriers can be easily fabricated to selectively target the cancer cells from normal cells [39].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 25,
      "context" : "The dendrimer is a highly branched, star-shaped macromolecules with nanometer-scale dimensions that are symmetric around the core [40,41].",
      "startOffset" : 130,
      "endOffset" : 137
    }, {
      "referenceID" : 26,
      "context" : "As most of the human body contains water, this ability of the nanocarrier becomes a major therapeutic efficiency while the other is the targeted delivery of the drug [44].",
      "startOffset" : 166,
      "endOffset" : 170
    }, {
      "referenceID" : 27,
      "context" : "This may be because of the lower pH, higher temperature, hydrophobic nature of the anticancer drugs and potential need of specific target ability [46].",
      "startOffset" : 146,
      "endOffset" : 150
    }, {
      "referenceID" : 5,
      "context" : "The major types of lung cancer include small-cell lung carcinoma, non-small-cell lung carcinoma and lung carcinoid tumor [48, 10].",
      "startOffset" : 121,
      "endOffset" : 129
    }, {
      "referenceID" : 28,
      "context" : "These factors suggest that ferulic acid loaded PLGA nanoparticle is a respectable therapeutic tool against lung cancer [50].",
      "startOffset" : 119,
      "endOffset" : 123
    }, {
      "referenceID" : 29,
      "context" : "Thus both the compounds were supposed to exhibit synergistic effect against lung cancer [52].",
      "startOffset" : 88,
      "endOffset" : 92
    }, {
      "referenceID" : 30,
      "context" : "Similar results were observed in the colony formation assay [53].",
      "startOffset" : 60,
      "endOffset" : 64
    }, {
      "referenceID" : 5,
      "context" : "The metastasis of breast cancer is often found to cause lung cancer in many cases [10, 48].",
      "startOffset" : 82,
      "endOffset" : 90
    }, {
      "referenceID" : 31,
      "context" : "The cell viability of the both breast cancer cell lines were decreased by the silk fibroin nanoparticle when compared to that of the SFCS nanoparticle [54].",
      "startOffset" : 151,
      "endOffset" : 155
    }, {
      "referenceID" : 32,
      "context" : "However, the TQLP was effectively supressed the proliferation of MCF-7 cells and exerted very low toxicity on normal periodontal ligament fibroblasts [57].",
      "startOffset" : 150,
      "endOffset" : 154
    }, {
      "referenceID" : 33,
      "context" : ", 2015, 00, 8-11 This journal is © The Royal Society of Chemistry 2015 nanoparticle as a novel therapeutic agent against breast cancer [58].",
      "startOffset" : 135,
      "endOffset" : 139
    }, {
      "referenceID" : 34,
      "context" : "The IC50 values showed that the gallic acid loaded PAMAM nanoparticles had a synergistic antiproliferative effect on the growth of MCF-7 cells [59].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 5,
      "context" : "It is more susceptible to the diet we consume as the colonic epithelial cells come in direct contact with them [10, 48].",
      "startOffset" : 111,
      "endOffset" : 119
    }, {
      "referenceID" : 35,
      "context" : "Hence, the polymeric micelles served as an excellent carrier of TP and reduced its toxicities [60].",
      "startOffset" : 94,
      "endOffset" : 98
    }, {
      "referenceID" : 36,
      "context" : "Therefore, this star-shaped honokiol micelle may be used to design a new dosage form [61].",
      "startOffset" : 85,
      "endOffset" : 89
    }, {
      "referenceID" : 37,
      "context" : "On the whole, the results demonstrate that encapsulation of TQ into nanoparticles enhances its anti-proliferative effects [62].",
      "startOffset" : 122,
      "endOffset" : 126
    }, {
      "referenceID" : 38,
      "context" : "However, the curcumin nanoparticle had no adverse or toxicity when investigated for in vivo systemic toxicity [64].",
      "startOffset" : 110,
      "endOffset" : 114
    }, {
      "referenceID" : 5,
      "context" : "The exposure to the ultraviolet radiation emitted by the sun is said to be a major cause of cancer [10, 48].",
      "startOffset" : 99,
      "endOffset" : 107
    }, {
      "referenceID" : 39,
      "context" : "Thus, the apigenin loaded poly (lactic-co-glycolide) nanoparticles possess potential ability for therapeutic management of skin cancer [66].",
      "startOffset" : 135,
      "endOffset" : 139
    }, {
      "referenceID" : 40,
      "context" : "Thus, the combretastatin A-4 encapsulation improved the efficacy of the doxorubicin [67].",
      "startOffset" : 84,
      "endOffset" : 88
    }, {
      "referenceID" : 41,
      "context" : "This inhibition included cell cycle phase arrest, changes in the level of cyclins D1 and D3 protein expression [68].",
      "startOffset" : 111,
      "endOffset" : 115
    }, {
      "referenceID" : 5,
      "context" : "According to the statistical reports, about 14,240 women will die from ovarian cancer in US alone and death from ovarian cancer is more common in North America and Europe than in Africa and Asia [10, 48].",
      "startOffset" : 195,
      "endOffset" : 203
    }, {
      "referenceID" : 42,
      "context" : "This was greater than the effect than the free honokiol [69].",
      "startOffset" : 56,
      "endOffset" : 60
    }, {
      "referenceID" : 43,
      "context" : "These results suggest that the curcumin loaded PLGA nanoparticle as one of the ideal therapeutic agent [70].",
      "startOffset" : 103,
      "endOffset" : 107
    }, {
      "referenceID" : 44,
      "context" : "The RES-BSNAP was found to induce apoptosis by releasing the cytochrome c and regulating the caspase-3, 9 and thereby indicating mitochondrial apoptotic pathway [71].",
      "startOffset" : 161,
      "endOffset" : 165
    }, {
      "referenceID" : 45,
      "context" : "These nanosystems which delivered curcumin showed excellent biocompatibility when studied with zebrafish embryo model [72].",
      "startOffset" : 118,
      "endOffset" : 122
    }, {
      "referenceID" : 5,
      "context" : "According to the estimation of American cancer society, about 180,890 new cases of prostate cancer are expected in 2016 which means 1 in 7 American men will be diagnosed with prostate cancer [10, 48].",
      "startOffset" : 191,
      "endOffset" : 199
    }, {
      "referenceID" : 46,
      "context" : "Thus the developed nanoparticles proved to exhibit selective toxicity against prostate cancer [73].",
      "startOffset" : 94,
      "endOffset" : 98
    }, {
      "referenceID" : 47,
      "context" : "The outcome was alike to that of the in vitro conditions and the tumor size was reduced significantly [75].",
      "startOffset" : 102,
      "endOffset" : 106
    }, {
      "referenceID" : 48,
      "context" : "Besides this the curcumin loaded PLGA nanospheres also highly inhibited NF-κB function when compared to free curcumin [76].",
      "startOffset" : 118,
      "endOffset" : 122
    }, {
      "referenceID" : 49,
      "context" : "Apart from these the availability of curcumin was improved during the co-administration of lipo-curcumin and lipo-resveratrol [77].",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 5,
      "context" : "However, cervical pre-cancers are diagnosed far more often than invasive cervical cancer [10, 48].",
      "startOffset" : 89,
      "endOffset" : 97
    }, {
      "referenceID" : 50,
      "context" : "This showed that the casein micelles proved to be a good drug carrier [78].",
      "startOffset" : 70,
      "endOffset" : 74
    }, {
      "referenceID" : 51,
      "context" : "Apart from this the cell viability of HeLa cells were significantly decreased by the curcumin loaded composite nanoparticle at a concentration of 500 μg/mL [79].",
      "startOffset" : 156,
      "endOffset" : 160
    }, {
      "referenceID" : 5,
      "context" : "About 39,230 new cases are estimated to be diagnosed by the American cancer society in 2016 for liver cancer [10, 48].",
      "startOffset" : 109,
      "endOffset" : 117
    }, {
      "referenceID" : 52,
      "context" : "Therefore, the work demonstrated that the liposome was a good carrier for the berberine [80].",
      "startOffset" : 88,
      "endOffset" : 92
    }, {
      "referenceID" : 53,
      "context" : "Thus the nanosuspension has improved the availability of the phytochemical to the cancer cells [81].",
      "startOffset" : 95,
      "endOffset" : 99
    }, {
      "referenceID" : 54,
      "context" : "The growth of HepG2 cells was significantly reduced by the apigenin micelles at lower concentrations than the free apigenein, which may be related to its improved hydrophilic characteristics [83].",
      "startOffset" : 191,
      "endOffset" : 195
    }, {
      "referenceID" : 55,
      "context" : "Hence, these results suggest that the delivery of resveratrol nanosuspension as a promising approach for treating tumors [85].",
      "startOffset" : 121,
      "endOffset" : 125
    }, {
      "referenceID" : 5,
      "context" : "It is usually due to usage of tobacco and obesity [10, 48].",
      "startOffset" : 50,
      "endOffset" : 58
    }, {
      "referenceID" : 56,
      "context" : "Thus it was found that the nanocurcumin possessed all the properties of curcumin with better solubility [86].",
      "startOffset" : 104,
      "endOffset" : 108
    }, {
      "referenceID" : 57,
      "context" : "Hence, the nano-drug delivery of curcumin is found to be one of the ideal therapy for cancer [87].",
      "startOffset" : 93,
      "endOffset" : 97
    }, {
      "referenceID" : 59,
      "context" : "However, the developed nanocarrier was found to be an excellent therapeutic device against CD44 overexpressing pancreatic cancer [89].",
      "startOffset" : 129,
      "endOffset" : 133
    }, {
      "referenceID" : 5,
      "context" : "Oral cancer is twice common in men than in women and American cancer society estimated 9,450 deaths due to it in 2016 [10, 48].",
      "startOffset" : 118,
      "endOffset" : 126
    }, {
      "referenceID" : 60,
      "context" : "Besides the DHAmicelles treated cells showed some physical signs of apoptosis [90].",
      "startOffset" : 78,
      "endOffset" : 82
    }, {
      "referenceID" : 61,
      "context" : "953 μg/ml along with visible DNA fragmentation in the KB cells [91].",
      "startOffset" : 63,
      "endOffset" : 67
    }, {
      "referenceID" : 5,
      "context" : "It is common among the children in the developed countries and about 24,450 deaths were estimated by the American cancer society [10, 48].",
      "startOffset" : 129,
      "endOffset" : 137
    }, {
      "referenceID" : 62,
      "context" : "The HPLC analysis showed the curcumin nanoparticle was more bioavailable and had a longer half-life than free curcumin [92].",
      "startOffset" : 119,
      "endOffset" : 123
    }, {
      "referenceID" : 63,
      "context" : "Overall, this combinational strategy has noteworthy promise than that of the drugs alone [93].",
      "startOffset" : 89,
      "endOffset" : 93
    }, {
      "referenceID" : 64,
      "context" : ", 2015,00, 5-11| 15 times higher than that of the free emodin in lungs and kidney [94].",
      "startOffset" : 82,
      "endOffset" : 86
    }, {
      "referenceID" : 65,
      "context" : "Moreover the nobiletinloaded chitosan nanoparticles showed considerable inhibition at IC50 of 8 μg/mL of cancerous cells, revealing their great potential for applications in cancer chemotherapy [95].",
      "startOffset" : 194,
      "endOffset" : 198
    }, {
      "referenceID" : 66,
      "context" : "Thus, the study suggests the ZER-NLC as a sustained-release drug carrier system for the treatment of leukemia [96].",
      "startOffset" : 110,
      "endOffset" : 114
    }, {
      "referenceID" : 67,
      "context" : "Hence, this study suggest that Res-loaded nanoparticles could be a potential chemotherapeutic formulation for malignant glioma therapy [97].",
      "startOffset" : 135,
      "endOffset" : 139
    }, {
      "referenceID" : 68,
      "context" : "Hence, the PEG-Chol nanosystem seems to allow stable drug carrier for curcumin [99].",
      "startOffset" : 79,
      "endOffset" : 83
    }, {
      "referenceID" : 69,
      "context" : "Therefore, the study offer an effective way to improve the anticancer efficiency of UA through nano-drug delivery system [100].",
      "startOffset" : 121,
      "endOffset" : 126
    }, {
      "referenceID" : 5,
      "context" : "One of the most prominent property is the anticancer effect of the phytochemicals as cancer claims to be the second leading cause of death worldwide [10].",
      "startOffset" : 149,
      "endOffset" : 153
    }, {
      "referenceID" : 44,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 231,
      "endOffset" : 238
    }, {
      "referenceID" : 35,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 267,
      "endOffset" : 278
    }, {
      "referenceID" : 44,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 267,
      "endOffset" : 278
    }, {
      "referenceID" : 69,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 267,
      "endOffset" : 278
    }, {
      "referenceID" : 45,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 298,
      "endOffset" : 302
    }, {
      "referenceID" : 56,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 324,
      "endOffset" : 331
    }, {
      "referenceID" : 62,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 324,
      "endOffset" : 331
    }, {
      "referenceID" : 37,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 382,
      "endOffset" : 392
    }, {
      "referenceID" : 62,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 382,
      "endOffset" : 392
    }, {
      "referenceID" : 64,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 382,
      "endOffset" : 392
    }, {
      "referenceID" : 28,
      "context" : "These natural compounds are found to supress the growth of cancer cells by inducing programmed cell death which is indicated by the notable changes such as DNA damage [49], increase ROS generation [49, 65], release of cytochrome C [71,98], activation of caspases 3/7 [60,71,100], cell cycle arrest [72], activation of NF-κB [86,92] and downregulation of MMP, BaX, Cyclin D and VEGF [62,92,94] along with visible morphological apoptotic changes [50].",
      "startOffset" : 444,
      "endOffset" : 448
    }, {
      "referenceID" : 28,
      "context" : "NCI-H460 non-small cell lung carcinoma cells Ferulic acid Poly-d,l-lactide-co-glycolide (PLGA) nanoparticles [50]",
      "startOffset" : 109,
      "endOffset" : 113
    }, {
      "referenceID" : 29,
      "context" : "A549 human lung adenocarcinomic cells β-Lapachone and Paclitaxel Poly(ethylene glycol)-co-poly(D,L-lactic acid) (PEG-PLA) polymer micelles [52]",
      "startOffset" : 139,
      "endOffset" : 143
    }, {
      "referenceID" : 30,
      "context" : "H292 lung cancer cells Luteolin Ploylactic acid and polyethylene glycol (PLA-PEG) nanoparticle [53]",
      "startOffset" : 95,
      "endOffset" : 99
    }, {
      "referenceID" : 31,
      "context" : "MCF-7 human breast adenocarcinoma cell line and MDA-MB-453 Curcumin Silk fibroin and chitosan (SFCS) polymers nanoparticles [54]",
      "startOffset" : 124,
      "endOffset" : 128
    }, {
      "referenceID" : 32,
      "context" : "adenocarcinoma cell line Thymoquinone Liposomes modified with Triton X-100 (XLP [57]",
      "startOffset" : 80,
      "endOffset" : 84
    }, {
      "referenceID" : 33,
      "context" : "MDA-MB-231 breast cancer cells Silibinin Lipid nanoparticles containing d-αtocopheryl polyethylene glycol 1000 succinate (TPGS) and phosphatidylcholine [58]",
      "startOffset" : 152,
      "endOffset" : 156
    }, {
      "referenceID" : 34,
      "context" : "adenocarcinoma cell line Gallic acid PAMAM dendrimers [59]",
      "startOffset" : 54,
      "endOffset" : 58
    }, {
      "referenceID" : 35,
      "context" : "HT29 human adenocarcinoma cells Triptolide MePEG-PLA copolymer micelle [60]",
      "startOffset" : 71,
      "endOffset" : 75
    }, {
      "referenceID" : 36,
      "context" : "CT26 murine colon carcinoma cells Honokiol Monomethoxy poly (ethylene glycol) (MPEG) and poly (ἐ-caprolactone) (PCL) star shaped micelle [61]",
      "startOffset" : 137,
      "endOffset" : 141
    }, {
      "referenceID" : 37,
      "context" : "Colorectal HCT 116 human colon cancer cells Thymoquinone Poly (lactide-co-glycolide) (PLGA) nanoparticles [62]",
      "startOffset" : 106,
      "endOffset" : 110
    }, {
      "referenceID" : 38,
      "context" : "CT-26 colon cancer cells Curcumin Curcumin nanoparticles anchored with C18PMH-PEG on the surface [64]",
      "startOffset" : 97,
      "endOffset" : 101
    }, {
      "referenceID" : 39,
      "context" : "A375 skin melanoma and HaCaT keratinocytes Apigenin Poly (lactic-co-glycolide) nanoparticles [65, 66]",
      "startOffset" : 93,
      "endOffset" : 101
    }, {
      "referenceID" : 40,
      "context" : "Melanoma B16 and B16F10 melanoma cells Combretastatin A-4 and Doxorubisin RGD (Arginylglycylaspartic acid)-modified liposomes [67]",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 41,
      "context" : "Mel 928 melanoma cells Epigallocatechin 3gallate (EGCG) polylactic acid-polyethylene glycol nanoparticles [68]",
      "startOffset" : 106,
      "endOffset" : 110
    }, {
      "referenceID" : 42,
      "context" : "A2780 human ovarian cancer cells Honokiol Monomethoxy poly(ethylene glycol)– poly(lactic acid) (MPEG–PLA) nanocarrier [69]",
      "startOffset" : 118,
      "endOffset" : 122
    }, {
      "referenceID" : 43,
      "context" : "Ovarian A2780CP ovarian cancer cells Curcumin Poly(lactic-co-glycolide) (PLGA) nanoparticle [70]",
      "startOffset" : 92,
      "endOffset" : 96
    }, {
      "referenceID" : 44,
      "context" : "SKOV ovarian cancer cells Resveratrol Bovine serum albumin nanoparticles [71]",
      "startOffset" : 73,
      "endOffset" : 77
    }, {
      "referenceID" : 45,
      "context" : "SKOV-3 ovarian cancer cells Curcumin Poly(2-hydroxyethyl methacrylate) [PHEMA] nanoparticles [72]",
      "startOffset" : 93,
      "endOffset" : 97
    }, {
      "referenceID" : 46,
      "context" : "LNCaP human prostate adenocarcinoma cells and PCa prostate cancer cells Polylactic acid-polyethylene glycol prostate-specific membrane antigen (PSMA) ligands [73]",
      "startOffset" : 158,
      "endOffset" : 162
    }, {
      "referenceID" : 47,
      "context" : "Prostate PCa prostate cancer cells Polylactic acid–polyethylene glycol (PLAPEG) nanocarrier [75]",
      "startOffset" : 92,
      "endOffset" : 96
    }, {
      "referenceID" : 48,
      "context" : "LNCaP human prostate adenocarcinoma cells, PC3 human prostate cancer cells and DU-145 PC3 human prostate cancer cells Curcumin Poly (lactic-coglycolic acid) (PLGA) nanospheres [76]",
      "startOffset" : 176,
      "endOffset" : 180
    }, {
      "referenceID" : 49,
      "context" : "PTEN-CaP8 Mouse prostate epithelium cancer cells Curcumin and resveratrol Curcumin and resveratrol nanoemulsions [77]",
      "startOffset" : 113,
      "endOffset" : 117
    }, {
      "referenceID" : 51,
      "context" : "Cervical HeLa cervical cancer cells Curcumin Alginate-chitosan-pluronic composite nanoparticles [79]",
      "startOffset" : 96,
      "endOffset" : 100
    }, {
      "referenceID" : 52,
      "context" : "Berberine Berberine polyethenyl glycol (PEG) liposome [80]",
      "startOffset" : 54,
      "endOffset" : 58
    }, {
      "referenceID" : 53,
      "context" : "HepG2 hepatocellular carcinoma cells Berberine Berberine and D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) nanosuspension [81]",
      "startOffset" : 133,
      "endOffset" : 137
    }, {
      "referenceID" : 54,
      "context" : "Hepatoma Apigenin Pluronic P123 and Solutol HS 15 polymeric [83] Page 17 of 21 RSC Advances",
      "startOffset" : 60,
      "endOffset" : 64
    }, {
      "referenceID" : 55,
      "context" : "Resveratrol Resveratrol and poloxamer 188 nanosuspension [85]",
      "startOffset" : 57,
      "endOffset" : 61
    }, {
      "referenceID" : 57,
      "context" : "Cholesteryl-hyaluronic acid (CHA) nanogel [87]",
      "startOffset" : 42,
      "endOffset" : 46
    }, {
      "referenceID" : 58,
      "context" : "Pancreatic MiaPaca pancreatic cancer cell line Difluorobenzylidene curcumin (CDF) Styrene-maleic acid copolymer (SMA) micelle [88]",
      "startOffset" : 126,
      "endOffset" : 130
    }, {
      "referenceID" : 59,
      "context" : "Poly(amidoamine) (PAMAM) and hyaluronic acid nanocarrier [89]",
      "startOffset" : 57,
      "endOffset" : 61
    }, {
      "referenceID" : 60,
      "context" : "Oral KB human oral cancer cells Dihydroartemisinin Methoxy poly(ethylene glycol)/poly(L-lactic acid) (mPEG) micelles [90]",
      "startOffset" : 117,
      "endOffset" : 121
    }, {
      "referenceID" : 61,
      "context" : "Ellagic acid Chitosan nanoparticle [91]",
      "startOffset" : 35,
      "endOffset" : 39
    }, {
      "referenceID" : 62,
      "context" : "KBM-5 myeloid leukemia cells Curcumin Poly (lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) nanoparticles [92]",
      "startOffset" : 117,
      "endOffset" : 121
    }, {
      "referenceID" : 63,
      "context" : "K562 myeloid leukemia cells Doxorubicin and Curcumin Poly- (D,L-lactide-co-glycolide) nanoparticles [93]",
      "startOffset" : 100,
      "endOffset" : 104
    }, {
      "referenceID" : 64,
      "context" : "Leukemia L1210 mouse lymphocytic leukemia cells and K562 myeloid leukemia cells Emodin D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) liposomes [94]",
      "startOffset" : 154,
      "endOffset" : 158
    }, {
      "referenceID" : 65,
      "context" : "7 Abelson murine leukemia virus-induced tumor cell lines Nobiletin Chitosan nanoparticles [95]",
      "startOffset" : 90,
      "endOffset" : 94
    }, {
      "referenceID" : 66,
      "context" : "Jurkat acute lymphoblastic leukemia cells Zerumbone Nanostructured lipid carriers [96]",
      "startOffset" : 82,
      "endOffset" : 86
    }, {
      "referenceID" : 67,
      "context" : "Glioma C6 glioma cells Resveratrol mPEG-PCL nanoparticles [97]",
      "startOffset" : 58,
      "endOffset" : 62
    }, {
      "referenceID" : 68,
      "context" : "Myeloma Myeloma cells Curcumin Poly(oxyethylene) cholesteryl ether (PEGChol micelles [99]",
      "startOffset" : 85,
      "endOffset" : 89
    }, {
      "referenceID" : 69,
      "context" : "Gastric SGC7901 gastric cancer cells Ursolic acid Methoxy poly(ethylene glycol)– polycaprolactone (mPEG–PCL) nanocarrier [100]",
      "startOffset" : 121,
      "endOffset" : 126
    }, {
      "referenceID" : 70,
      "context" : "Previous studies have shown phytochemicals when combined have improved cytotoxicity towards cancer cells [101].",
      "startOffset" : 105,
      "endOffset" : 110
    } ],
    "year" : 2016,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. View Article Online",
    "creator" : "Aspose Ltd."
  }
}